DuPont de Nemours (DD) 10-Q 4 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-38196
Entity Registrant Name	DUPONT DE NEMOURS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	81-1224539
Entity Address, Address Line One	974 Centre Road
Entity Address, Address Line Two	Building 730
Entity Address, City or Town	Wilmington
Entity Address, State or Province	DE
Entity Address, Postal Zip Code	19805
City Area Code	302
Local Phone Number	774-3034
Title of 12(b) Security	Common Stock, par value $0.01 per share
Trading Symbol	DD
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Share Outstanding		532,142,336
Entity Central Index Key	0001666700
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Net sales		$ 3,976	$ 3,670
Cost of sales		2,512	2,319
Research and development expenses		156	173
Selling, general and administrative expenses		456	482
Amortization of intangibles		167	178
Restructuring and asset related charges - net		2	398
Goodwill impairment charge		0	533
Integration and separation costs		6	123
Equity in earnings of nonconsolidated affiliates		26	39
Sundry income (expense) - net		16	212
Interest expense		146	171
Income (loss) from continuing operations before income taxes		573	(456)
Provision for income taxes on continuing operations		32	94
Income (loss) from continuing operations, net of tax		541	(550)
Income (loss) from discontinued operations, net of tax		4,857	(60)
Net income (loss)		5,398	(610)
Net income attributable to noncontrolling interests		4	6
Net income (loss) available for DuPont common stockholders		$ 5,394	$ (616)
Per common share data:
Earnings (loss) per common share from continuing operations - basic (in usd per share)		$ 0.89	$ (0.75)
Earnings (loss) per common share from discontinued operations - basic (in usd per share)		8.03	(0.08)
Earnings (loss) per common share - basic (in usd per share)	[1]	8.92	(0.83)
Earnings (loss) per common share from continuing operations - diluted (in usd per share)		0.89	(0.75)
Earnings (loss) per common share from discontinued operations - diluted (in usd per share)		8.01	(0.08)
Earnings (loss) per common share - diluted (in usd per share)	[1]	$ 8.90	$ (0.83)
Weighted-average common shares outstanding - basic (in shares)		604.8	738.6
Weighted-average common shares outstanding - diluted (in shares)		606.3	738.6
[1]	Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ 5,398	$ (610)
Other comprehensive (loss) income, net of tax
Cumulative translation adjustments	(484)	(404)
Pension and other post-employment benefit plans	12	2
Split-off of N&B	258	0
Total other comprehensive loss	(214)	(402)
Comprehensive income (loss)	5,184	(1,012)
Comprehensive loss attributable to noncontrolling interests, net of tax	(3)	(2)
Comprehensive income (loss) attributable to DuPont	$ 5,187	$ (1,010)

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 4,384	$ 2,544
Marketable securities	2,001	0
Accounts and notes receivable - net	2,609	2,421
Inventories	2,499	2,393
Other current assets	184	181
Assets held for sale	863	810
Assets of discontinued operations	0	20,659
Total current assets	12,540	29,008
Property, plant and equipment - net of accumulated depreciation (March 31, 2021 - $4,359; December 31, 2020 - $4,256)	6,744	6,867
Other Assets
Goodwill	18,511	18,702
Other intangible assets	7,857	8,072
Restricted cash	0	6,206
Investments and noncurrent receivables	1,059	1,047
Deferred income tax assets	177	190
Deferred charges and other assets	916	812
Total other assets	28,520	35,029
Total Assets	47,804	70,904
Current Liabilities
Short-term borrowings and finance lease obligations	1,997	1
Accounts payable	2,219	2,222
Income taxes payable	189	169
Accrued and other current liabilities	1,129	1,084
Liabilities related to assets held for sale	133	140
Liabilities of discontinued operations	0	8,610
Total current liabilities	5,667	12,226
Long-Term Debt	10,625	15,611
Other Noncurrent Liabilities
Deferred income tax liabilities	1,918	2,053
Pension and other post-employment benefits - noncurrent	1,040	1,110
Other noncurrent obligations	849	834
Total other noncurrent liabilities	3,807	3,997
Total Liabilities	20,099	31,834
Commitments and contingent liabilities
Stockholders' Equity
Common stock (authorized 1,666,666,667 shares of $0.01 par value each; issued 2021: 532,090,582 shares; 2020: 734,204,054 shares)	5	7
Additional paid-in capital	49,964	50,039
Accumulated deficit	(22,618)	(11,586)
Accumulated other comprehensive (loss) income	(163)	44
Total DuPont stockholders' equity	27,188	38,504
Noncontrolling interests	517	566
Total equity	27,705	39,070
Total Liabilities and Equity	$ 47,804	$ 70,904

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accumulated depreciation	$ 4,359	$ 4,256
Shares authorized	1,666,666,667	1,666,666,667
Par value (in usd per share)	$ 0.01	$ 0.01
Shares issued	532,090,582	734,204,054

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended		22 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021
Operating Activities
Net income (loss)	$ 5,398	$ (610)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	328	345
Goodwill impairment charge	0	533
Financing Activities
Purchases of common stock	(500)		$ (1,500)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(37)	(45)
(Decrease) increase in cash, cash equivalents and restricted cash	(4,377)	205
Cash, cash equivalents and restricted cash at beginning of period	8,767	1,569
Cash, cash equivalents and restricted cash from discontinued operations, beginning of period	8	8
Cash, cash equivalents and restricted cash at beginning of period	8,775	1,577
Cash, cash equivalents and restricted cash at end of period	4,398	1,776	4,398
Cash, cash equivalents and restricted cash from discontinued operations, end of period	0	6	0
Cash, cash equivalents and restricted cash at end of period	4,398	1,782	$ 4,398
Total Company
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	391	772
Credit for deferred income tax and other tax related items	(105)	(164)
Earnings of nonconsolidated affiliates in excess of dividends received	(20)	(31)
Net periodic pension benefit cost	2	7
Pension contributions	(26)	(26)
Net gain on sales and split-offs of assets, businesses and investments	(4,982)	(197)
Restructuring and asset related charges - net	4	404
Goodwill impairment charge	0	533
Other net loss	53	49
Changes in assets and liabilities, net of effects of acquired and divested companies:
Accounts and notes receivable	(228)	(134)
Inventories	(174)	(134)
Accounts payable	92	236
Other assets and liabilities, net	(27)	13
Cash provided by operating activities	378	718
Investing Activities
Capital expenditures	(283)	(481)
Proceeds from sales of property and businesses, net of cash divested	31	427
Acquisitions of property and businesses, net of cash acquired	(11)	(73)
Purchases of investments	(2,001)	(1)
Other investing activities, net	4	4
Cash used for investing activities	(2,260)	(124)
Financing Activities
Changes in short-term notes payable	0	69
Proceeds from issuance of long-term debt	0	25
Payments on long-term debt	(3,000)	(1)
Purchases of common stock	(500)	(232)
Proceeds from issuance of Company stock	90	34
Employee taxes paid for share-based payment arrangements	(15)	(12)
Distributions to noncontrolling interests	(19)	(6)
Dividends paid to stockholders	(161)	(222)
Cash transferred to IFF at split-off	(100)	0
Other financing activities, net	(3)	1
Cash used for financing activities	(2,458)	(344)
N&B Segment
Financing Activities
Proceeds from issuance of long-term debt	$ 1,250	$ 0

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit)Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comp Loss	Treasury Stock	Non-controlling Interests
Beginning balance at Dec. 31, 2019	$ 41,556	$ (3)	$ 7	$ 50,796	$ (8,400)	$ (3)	$ (1,416)	$ 0	$ 569
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(610)				(616)				6
Other comprehensive income (loss)	(402)						(394)		(8)
Dividends ($0.30 per common share)	(222)			(222)
Common stock issued/sold	34			34
Stock-based compensation	30			30
Distributions to non-controlling interests	(6)								(6)
Purchases of treasury stock	(232)							(232)
Retirement of treasury stock					(232)			232
Other	(28)			(33)					5
Ending balance at Mar. 31, 2020	40,117		7	50,605	(9,251)		(1,810)	0	566
Beginning balance at Dec. 31, 2020	39,070		7	50,039	(11,586)		44	0	566
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	5,398				5,394				4
Other comprehensive income (loss)	(214)						(207)		(7)
Dividends ($0.30 per common share)	(161)			(161)
Common stock issued/sold	90			90
Stock-based compensation	(4)			(4)
Distributions to non-controlling interests	(19)								(19)
Purchases of treasury stock	(500)							(500)
Retirement of treasury stock	0				(500)			500
Split-off of N&B	(15,955)		(2)		(15,926)				(27)
Ending balance at Mar. 31, 2021	$ 27,705		$ 5	$ 49,964	$ (22,618)		$ (163)	$ 0	$ 517

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parentheticals) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Dividends declared (in usd per share)	$ 0.30	$ 0.30

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Interim Financial Statements The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, collectively referred to as the “2020 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained. Basis of Presentation Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("TDCC") and E. I. du Pont de Nemours and Company ("EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, TDCC and EID became subsidiaries of DowDuPont (the "DWDP Merger"). Except as otherwise indicated by the context, the term "TDCC" includes TDCC and its consolidated subsidiaries and "EID" includes EID and its consolidated subsidiaries. On April 1, 2019, the Company completed the separation of the materials science business through the spin-off of Dow Inc., (“Dow”) including Dow’s subsidiary TDCC (the “Dow Distribution”). On June 1, 2019, the Company completed the separation of the agriculture business through the spin-off of Corteva, Inc. (“Corteva”) including Corteva’s subsidiary EID, (the “Corteva Distribution" and together with the Dow Distribution, the “DWDP Distributions”). Following the Corteva Distribution, DuPont holds the specialty products business as continuing operations. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD." N&B Transaction On February 1, 2021, DuPont completed the separation and distribution of the Nutrition & Biosciences business segment (the "N&B Business"), and merger of Nutrition & Biosciences, Inc. (“N&B”), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF"). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). See Note 2 for more information. The financial position of DuPont as of March 31, 2021 and December 31, 2020 and the results of operations of DuPont for the three months ended March 31, 2021 and 2020 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B. 2021 Segment Realignment Immediately following the separation and distribution of the N&B Business, the Company made changes to its management and reporting structure (the “2021 Segment Realignment”) (see Note 22 for additional details). The reporting changes have been retrospectively reflected for all periods presented.

ACQUISITIONS AND DIVESTITURES

ACQUISITIONS AND DIVESTITURES	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES Laird Performance Materials On March 8, 2021, the Company announced that it had entered into a definitive agreement with Advent International to acquire Laird Performance Materials for $2.3 billion. The acquisition is expected to close in the third quarter of 2021, subject to regulatory approvals and other customary closing conditions, and will be part of the Electronic & Industrials segment. The Company intends to pay for the acquisition from existing cash balances. N&B Transaction On February 1, 2021, DuPont completed the separation and distribution of the N&B Business, and merger of N&B, a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of IFF. The distribution was effected through an exchange offer where, on the terms and subject to the conditions of the Exchange Offer, eligible participating DuPont stockholders had the option to tender all, some or none of their shares of common stock, par value $0.01 per share, of DuPont (the “DuPont Common Stock”) for a number of shares of common stock, par value $0.01 per share, of N&B (the “N&B Common Stock”) and which resulted in all shares of N&B Common Stock being distributed to DuPont stockholders that participated in the Exchange Offer. The consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). The N&B Transaction was subject to IFF shareholder approval, customary regulatory approvals, tax authority rulings including a favorable private letter ruling from the U.S. Internal Revenue Service which confirms the N&B Transaction to be free of U.S. federal income tax, and expiration of the public exchange offer. DuPont does not have an ownership interest in IFF as a result of the N&B Transaction. In the Exchange Offer, DuPont accepted approximately 197.4 million shares of its common stock in exchange for about 141.7 million shares of N&B Common Stock as of the date of the N&B Transaction. As a result, DuPont reduced its common stock outstanding by 197.4 million shares of DuPont Common Stock. In the N&B Merger, each share of N&B Common Stock was automatically converted into the right to receive one share of IFF common stock, par value $0.125 per share, based on the terms of the N&B Merger Agreement. The results of operations of N&B are presented as discontinued operations as summarized below: Three Months Ended March 31, 2021 Three Months Ended In millions Net sales $ 507 $ 1,551 Cost of sales 352 999 Research and development expenses 21 63 Selling, general and administrative expenses 44 151 Amortization of intangibles 38 355 Restructuring and asset related charges - net 1 6 Integration and separation costs 149 74 Sundry income (expense) - net (2) (1) Interest expense 13 12 Loss from discontinued operations before income taxes (113) (110) Benefit from income taxes on discontinued operations (21) (50) Loss from discontinued operations, net of tax (92) (60) Non-taxable gain on split-off 4,954 — Income (loss) from discontinued operations attributable to DuPont stockholders, net of tax $ 4,862 $ (60) The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to N&B: Three Months Ended March 31, 2021 Three Months Ended In millions Depreciation and amortization $ 63 $ 427 Capital expenditures $ 27 $ 92 The carrying amount of major classes of assets and liabilities that were included in discontinued operations at December 31, 2020 related to N&B consist of the following: In millions December 31, 2020 Assets Accounts and notes receivable - net $ 1,130 Inventories 1,333 Other current assets 65 Investments and noncurrent receivables 36 Property, plant, and equipment - net 3,118 Goodwill 11,542 Other intangible assets - net 3,072 Deferred income tax assets 44 Deferred charges and other assets 319 Total assets of discontinued operations $ 20,659 Liabilities Short-term borrowings and finance lease obligations $ 4 Accounts Payable 742 Income taxes payable 36 Accrued and other current liabilities 301 Long-term debt 6,195 Deferred income tax liabilities 852 Pension and other post employment benefits - noncurrent 238 Other noncurrent obligations 242 Total liabilities of discontinued operations $ 8,610 In connection with the N&B Transaction and in accordance with the terms of the N&B Transaction Agreements, defined below, prior to consummation of the Exchange Offer and the N&B Merger, DuPont received a one-time cash payment of approximately $7.3 billion, (the "Special Cash Payment"), which is subject to post-closing adjustment pursuant to the terms of the N&B Separation and Distribution Agreement. The special cash payment was partially funded by an offering of $6.25 billion of senior unsecured notes (the “N&B Notes Offering”). The net proceeds of approximately $6.2 billion from the N&B Notes Offering were deposited into an escrow account and at December 31, 2020, are reflected as restricted cash in the Company’s interim Condensed Consolidated Balance Sheets. In order to fund the remainder of the Special Cash Payment, on February 1, 2021, N&B borrowed $1.25 billion under a senior unsecured term loan agreement (the "N&B Term Loan"). The obligations and liabilities associated with the N&B Notes Offering and the N&B Term Loan were separated from the Company on February 1, 2021 upon consummation of the N&B Transaction. The obligations and liabilities of $6.2 billion associated with the N&B Notes Offering are classified as "Liabilities of discontinued operations" in the Company's interim Condensed Consolidated Balance Sheets. The Company recognized a non-taxable gain of approximately $4,954 million on the N&B Transaction. The gain is recorded in "Income (loss) from discontinued operations, net of tax" in the Company's interim Consolidated Statements of Operations for the three months ended March 31, 2021. N&B Transaction Agreements In connection with the N&B Transaction, effective December 15, 2019, the Company, as previously discussed, entered into the following agreements: • A Separation and Distribution Agreement, subsequently amended and joined by Neptune Merger Sub II Inc., a subsidiary of IFF on January 22, 2021, and as amended further on February 1, 2021 (as amended, the “N&B Separation and Distribution Agreement”) with N&B and IFF, which, among other things, governs the separation of the N&B Business from DuPont and certain other post-closing obligations between DuPont and N&B related thereto; • An Agreement and Plan of Merger, (the “N&B Merger Agreement”) with N&B, IFF and Neptune Merger Sub I Inc., governing the N&B Merger and related matters; and • An Employee Matters Agreement, subsequently amended on January 22, 2021, (as amended, the “N&B Employee Matters Agreement Agreement”), with N&B and IFF, which, among other things, allocates among the parties the pre- and post-closing liabilities in respect of the current and former employees of the N&B Business (including liabilities in respect of employee compensation and benefit plans). In connection with the closing of the N&B Transaction, and effective February 1, 2021, the Company entered into the following agreements: • DuPont, N&B and certain of their subsidiaries entered into an Intellectual Property Cross-License Agreement (the “N&B IP Cross-License Agreement”). The IP Cross-License Agreement sets forth the terms and conditions under which the applicable parties may use in their respective businesses certain know-how (including trade secrets), copyrights, design rights, software, and patents, allocated to another party pursuant to the N&B Separation and Distribution Agreement, and pursuant to which N&B may use certain standards retained by DuPont. All licenses under the IP Cross-License Agreement are non-exclusive, worldwide, and royalty-free; and • DuPont, N&B and IFF entered into a Tax Matters Agreement (the “N&B Tax Matters Agreement”), which governs the parties’ rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings, the preservation of the expected tax-free status of the transactions contemplated by the N&B Separation and Distribution Agreement, and other matters regarding taxes. See Note 6 for additional information on the N&B Tax Matters Agreement. Assets Held for Sale In October 2020, the Company entered into a definitive agreement to sell its Biomaterials business unit, which includes the Company's equity method investment in DuPont Tate & Lyle Bio Products. In January 2021, the Company entered into separate definitive agreements to sell its Clean Technologies and Solamet® businesses. These divestitures, subject to regulatory approval and customary closing conditions, are expected to close in the second half of 2021 and generate in aggregate pre-tax cash proceeds of about $920 million. The Company also signed a non-binding letter of intent to sell Chestnut Run labs, a portion of the Company's Chestnut Run campus. This transaction is expected to close within one year. The assets and liabilities associated with the Biomaterials and Clean Technologies businesses met the held for sale criteria at December 31, 2020, and the assets and liabilities associated with the Solamet® business and Chestnut Run labs met the held for sale criteria at March 31, 2021. The Biomaterials, Clean Technologies and Solamet® businesses are reported in Corporate. The following table summarizes the carrying value of the major assets and liabilities of the Biomaterials, Clean Technologies, and Solamet® business units and Chestnut Run labs as of March 31, 2021 (collectively, the “Held for Sale Disposal Group”) and the Biomaterials and Clean Technologies business units as of December 31, 2020: In millions March 31, 2021 December 31, 2020 Assets Accounts and notes receivable - net $ 68 $ 63 Inventories 72 75 Other current assets 36 35 Investments and noncurrent receivables 166 164 Property, plant and equipment - net 83 34 Goodwill 267 267 Other intangible assets 168 168 Deferred charges and other assets 3 4 Assets held for sale $ 863 $ 810 Liabilities Accounts payable $ 44 $ 40 Income taxes payable 3 1 Accrued and other current liabilities 40 50 Deferred income tax liabilities 29 30 Pension and other post-employment benefits - noncurrent 1 1 Other noncurrent obligations 16 18 Liabilities related to assets held for sale $ 133 $ 140 Sale of Compound Semiconductor Solutions In the first quarter of 2020, the Company completed the sale of its Compound Semiconductor Solutions business unit, a part of the Electronics & Industrial segment, to SK Siltron. The proceeds received in the first quarter of 2020 related to the sale of the business were approximately $420 million. For the three months ended March 31,2020, a pre-tax gain of $197 million ($102 million net of tax) was recorded in "Sundry income (expense) - net" in the Company's interim Consolidated Statements of Operations. Integration and Separation Costs Integration and separation costs primarily consist of financial advisory, information technology, legal, accounting, consulting, and other professional advisory fees. In the first quarter of 2021, these costs were primarily associated with the execution of activities related to strategic initiatives including the divestiture of the Held for Sale Disposal Group. In the first quarter of 2020, these costs were primarily associated with the execution of activities related to the post-DWDP Merger integration and the DWDP Distributions. These costs are recorded within "Integration and separation costs" within the interim Consolidated Statements of Operations. Three Months Ended March 31, In millions 2021 2020 Integration and separation costs $ 6 $ 123

REVENUE

REVENUE	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Products Substantially all of DuPont's revenue is derived from product sales. Product sales consist of sales of DuPont's products to supply manufacturers and distributors. DuPont considers purchase orders, which in some cases are governed by master supply agreements, to be a contract with a customer. Contracts with customers are considered to be short-term when the time between order confirmation and satisfaction of the performance obligations is equal to or less than one year. Disaggregation of Revenue The Company disaggregates its revenue from contracts with customers by segment and business or major product line and geographic region, as the Company believes it best depicts the nature, amount, timing and uncertainty of its revenue and cash flows. On February 1, 2021, the Company realigned and renamed certain businesses as part of the 2021 Segment Realignment resulting in changes to its management and reporting structure (see Note 22 for additional details). In conjunction with the 2021 Segment Realignment, DuPont made the following changes to its major product lines: • Within Electronics & Industrial (formerly known as Electronics & Imaging) realigned product lines to include businesses formerly in Transportation & Industrial and renamed the Image Solutions product lines as Industrial Solutions; • Renamed Safety & Construction as Water & Protection; • Realigned certain businesses from the former Non-Core segment and renamed product lines within Mobility & Materials (formerly known as Transportation & Industrial) as Advanced Solutions, Engineering Polymers, and Performance Resins. Net Trade Revenue by Segment and Business or Major Product Line Three Months Ended March 31, In millions 2021 2020 Industrial Solutions $ 458 $ 412 Interconnect Solutions 330 266 Semiconductor Technologies 512 437 Electronics & Industrial $ 1,300 $ 1,115 Safety Solutions $ 637 $ 631 Shelter Solutions 360 348 Water Solutions 331 297 Water & Protection $ 1,328 $ 1,276 Advanced Solutions $ 382 $ 306 Engineering Polymers 497 519 Performance Resins 336 266 Mobility & Materials $ 1,215 $ 1,091 Corporate 1 $ 133 $ 188 Total $ 3,976 $ 3,670 1. Corporate net sales reflect activity of to be divested and previously divested businesses. Net Trade Revenue by Geographic Region Three Months Ended March 31, In millions 2021 2020 U.S. & Canada $ 1,051 $ 1,152 EMEA 1 830 791 Asia Pacific 1,950 1,581 Latin America 145 146 Total $ 3,976 $ 3,670 1. Europe, Middle East and Africa. Contract Balances From time to time, the Company enters into arrangements in which it receives payments from customers based upon contractual billing schedules. The Company records accounts receivables when the right to consideration becomes unconditional. Contract assets include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Contract liabilities primarily reflect deferred revenue from advance payment for product that the Company has received from customers. The Company classifies deferred revenue as current or noncurrent based on the timing of when the Company expects to recognize revenue. Revenue recognized in the first three months of 2021 from amounts included in contract liabilities at the beginning of the period and the amount of contract assets reclassified to receivables as a result of the right to the transaction consideration becoming unconditional were insignificant. The Company did not recognize any asset impairment charges related to contract assets during the period. Contract Balances March 31, 2021 December 31, 2020 In millions Accounts and notes receivable - trade 1 $ 2,077 $ 1,911 Deferred revenue - current 2 $ 32 $ 16 Deferred revenue - noncurrent 3 $ 20 $ 21 1. Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

RESTRUCTURING AND ASSET RELATED

RESTRUCTURING AND ASSET RELATED CHARGES - NET	3 Months Ended
	Mar. 31, 2021
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET RELATED CHARGES - NET	RESTRUCTURING AND ASSET RELATED CHARGES - NET Charges for restructuring programs and asset related charges, which includes asset impairments, were $2 million for the three months ended March 31, 2021 and $398 million for the three months ended March 31, 2020. These charges were recorded in "Restructuring and asset related charges - net" in the interim Consolidated Statements of Operations. The total liability related to restructuring programs was $55 million at March 31, 2021 and $96 million at December 31, 2020, recorded in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. Restructuring activity consists of the following programs: 2020 Restructuring Program In the first quarter of 2020, the Company approved restructuring actions designed to capture near-term cost reductions and to further simplify certain organizational structures in anticipation of the N&B Transaction (the "2020 Restructuring Program"). The Company recorded pre-tax restructuring charges of $170 million inception-to-date, consisting of severance and related benefit costs of $118 million and asset related charges of $52 million. The following tables summarize the charges related to the 2020 Restructuring Program: Three Months Ended March 31, In millions 2021 2020 Severance and related benefit costs $ — $ 90 Asset related charges 2 15 Total restructuring and asset related charges - net $ 2 $ 105 2020 Restructuring Program Charges by Segment Three Months Ended March 31, In millions 2021 2020 Electronics & Industrial $ — $ 4 Water & Protection — 20 Mobility & Materials — 24 Corporate 2 57 Total $ 2 $ 105 The following table summarizes the activities related to the 2020 Restructuring Program: 2020 Restructuring Program Severance and Related Benefit Costs Asset Related Charges Total In millions Reserve balance at December 31, 2020 $ 62 $ — $ 62 Year-to-date restructuring charges $ — $ 2 $ 2 Charges against the reserve — (2) (2) Cash payments $ (26) $ — $ (26) Reserve balance at March 31, 2021 $ 36 $ — $ 36 Total liabilities related to the 2020 Restructuring Program were $36 million at March 31, 2021 and $62 million at December 31, 2020, respectively, and recorded in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The 2020 Restructuring Program is considered substantially complete. 2019 Restructuring Program During the second quarter of 2019 and in connection with the ongoing integration activities, DuPont approved restructuring actions to simplify and optimize certain organizational structures following the completion of the DWDP Distributions (the "2019 Restructuring Program"). The Company has recorded pre-tax restructuring charges of $124 million inception-to-date, consisting of severance and related benefit costs of $97 million and asset related charges of $27 million. Total liabilities related to the 2019 Restructuring Program were $6 million at March 31, 2021 and $14 million at December 31, 2020, respectively, and recorded in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The 2019 Restructuring Program is considered substantially complete. DowDuPont Cost Synergy Program In September and November 2017, the Company approved post-merger restructuring actions under the DowDuPont Cost Synergy Program (the "Synergy Program"), which was designed to integrate and optimize the organization following the DWDP Merger and in preparation for the DWDP Distributions. The Company has recorded pre-tax restructuring charges attributable to the continuing operations of DuPont of $346 million inception-to-date, consisting of severance and related benefit costs of $138 million, asset related charges of $159 million and contract termination charges of $49 million. Total liabilities related to the Synergy Program were $13 million at March 31, 2021 and $20 million at December 31, 2020, respectively, and recorded in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets. The Synergy Program is considered substantially complete. Asset Impairments The Company reviews and evaluates its long-lived assets for impairment when events and changes in circumstances indicate that the related carrying amount of such assets may not be recoverable and may exceed their fair value. For purposes of determining impairment, assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within Corporate gave rise to fair value indicators and, thus, triggering events requiring the Company to perform a recoverability assessment related to its Biomaterials business unit. The Company performed a long-lived asset impairment test and determined that, based on undiscounted cash flows, the carrying amount of certain long-lived assets was not recoverable. Accordingly, the Company estimated the fair value of these assets using a market approach utilizing Level 3 unobservable inputs. As a result, the Company recognized a $270 million pre-tax impairment charge recorded within “Restructuring and asset related charges - net” in the interim Consolidated Statements of Operation for the three months ended March 31, 2020 with the charge impacting definite-lived intangible assets and property, plant, and equipment.

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUPPLEMENTARY INFORMATION	SUPPLEMENTARY INFORMATION Sundry Income (Expense) - Net Three Months Ended March 31, In millions 2021 2020 Non-operating pension and other post-employment benefit (OPEB) credits $ 12 $ 11 Interest income 2 2 Net gain on divestiture and sales of other assets and investments 1 27 197 Foreign exchange losses, net (9) (3) Miscellaneous (expenses) income - net 2 (16) 5 Sundry income (expense) - net $ 16 $ 212 1. The three months ended March 31, 2021 reflects income of $24 million related to the gain on sale of assets within the Electronics & Industrial segment. The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Industrial segment. 2. The three months ended March 31, 2021 includes an impairment charge of approximately $15 million related to Chestnut Run labs, which is part of the Held for Sale Disposal Group. Cash, Cash Equivalents and Restricted Cash At December 31, 2020, the Company had approximately $6.2 billion recorded within non-current “Restricted cash” in the Consolidated Balance Sheet. The restricted cash relates to net proceeds received from an offering of $6.25 billion of senior unsecured notes (the "N&B Notes Offering") associated with the N&B transaction. On February 1, 2021 this amount was released from escrow as part of the N&B Transaction and is no longer restricted. The liability from the N&B Notes Offering was classified as "Liabilities of discontinued operations" in the Company's interim Condensed Consolidated Balance Sheet as of December 31, 2020. See Note 2 for further discussion of the Company's divestiture of the N&B business.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Each year the Company files hundreds of tax returns in the various national, state and local income taxing jurisdictions in which it operates. These tax returns are subject to examination and possible challenge by the tax authorities. Positions challenged by the tax authorities may be settled or appealed by the Company. As a result, there is an uncertainty in income taxes recognized in the Company’s financial statements in accordance with accounting for income taxes and accounting for uncertainty in income taxes. The ultimate resolution of such uncertainties is not expected to have a material impact on the Company's results of operations. The Company's effective tax rate fluctuates based on, among other factors, where income is earned and the level of income relative to tax attributes. The effective tax rate on continuing operations for the first quarter of 2021 was 5.6 percent, compared with an effective tax rate of (20.6) percent for the first quarter of 2020. The effective tax rate for the first quarter of 2021 was principally the result of a $59 million tax benefit related to the step-up in tax basis in the goodwill of the Company’s European regional headquarters legal entity. The effective tax rate for the first quarter of 2020 was principally the result of the non-tax-deductible goodwill impairment charge impacting Corporate. See Note 12 for more information regarding the goodwill impairment charge. Certain internal distributions and reorganizations that occurred in preparation for the N&B Transaction qualified as tax-free transactions under the applicable sections of the Internal Revenue Code. If the aforementioned transactions were to fail to qualify for non-recognition treatment for U.S. federal income tax purposes, then the Company could be subject to significant tax liability. In connection with the closing of the N&B Transaction, DuPont, N&B and IFF entered into the N&B Tax Matters Agreement. Under the N&B Tax Matters Agreement, the Company would generally be allocated such liability and not be indemnified, unless certain non-qualifying actions are undertaken by N&B or IFF. To the extent that the Company is responsible for any such liability, there could be a material adverse impact on the Company's business, financial condition, results of operations and cash flows in future reporting periods. For periods between the DWDP Merger and the DWDP Distributions, DuPont's consolidated federal income tax group and consolidated tax return included the Dow and Corteva entities. Generally, the consolidated tax liability of the DuPont U.S. tax group for each year was apportioned among the members of the consolidated group in accordance with the terms of the Amended and Restated DWDP Tax Matters Agreement. DuPont, Corteva and Dow intend that to the extent Federal and/or State corporate income tax liabilities are reduced through the utilization of tax attributes of the other, settlement of any receivable and payable generated from the use of the other party’s sub-group attributes will be in accordance with the Amended and Restated DWDP Tax Matters Agreement.

EARNINGS PER SHARE CALCULATIONS

EARNINGS PER SHARE CALCULATIONS	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE CALCULATIONS	EARNINGS PER SHARE CALCULATIONS The following tables provide earnings per share calculations for the three months ended March 31, 2021 and 2020: Net Income for Earnings Per Share Calculations - Basic & Diluted Three Months Ended March 31, In millions 2021 2020 Income (loss) from continuing operations, net of tax $ 541 $ (550) Net income from continuing operations attributable to noncontrolling interests 4 6 Income (loss) from continuing operations attributable to common stockholders $ 537 $ (556) Income (loss) from discontinued operations, net of tax 4,857 (60) Net income from discontinued operations attributable to noncontrolling interests — — Income (loss) from discontinued operations attributable to common stockholders 4,857 (60) Net income (loss) attributable to common stockholders $ 5,394 $ (616) Earnings Per Share Calculations - Basic Three Months Ended March 31, Dollars per share 2021 2020 Earnings (loss) from continuing operations attributable to common stockholders $ 0.89 $ (0.75) Earnings (loss) from discontinued operations, net of tax 8.03 (0.08) Earnings (loss) attributable to common stockholders 2 $ 8.92 $ (0.83) Earnings Per Share Calculations - Diluted Three Months Ended March 31, Dollars per share 2021 2020 Earnings (loss) from continuing operations attributable to common stockholders $ 0.89 $ (0.75) Earnings (loss) from discontinued operations, net of tax 8.01 (0.08) Earnings (loss) attributable to common stockholders 2 $ 8.90 $ (0.83) Share Count Information Three Months Ended March 31, Shares in millions 2021 2020 Weighted-average common shares - basic 604.8 738.6 Plus dilutive effect of equity compensation plans 1.5 — Weighted-average common shares - diluted 606.3 738.6 Stock options and restricted stock units excluded from EPS calculations 1 2.2 6.4 1. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive. 2. Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

ACCOUNTS AND NOTES RECEIVABLE -

ACCOUNTS AND NOTES RECEIVABLE - NET	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
ACCOUNTS AND NOTES RECEIVABLE - NET	ACCOUNTS AND NOTES RECEIVABLE - NET In millions March 31, 2021 December 31, 2020 Accounts receivable – trade 1 $ 2,015 $ 1,850 Notes receivable – trade 62 61 Other 2 532 510 Total accounts and notes receivable - net $ 2,609 $ 2,421 1. Accounts receivable – trade is net of allowances of $33 million at March 31, 2021 and at December 31, 2020. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts. 2. Other includes receivables in relation to value added tax, fair value of derivative instruments, indemnification assets, and general sales tax and other taxes. No individual group represents more than ten percent of total receivables.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories March 31, 2021 December 31, 2020 In millions Finished goods $ 1,526 $ 1,503 Work in process 552 515 Raw materials 294 251 Supplies 127 124 Total inventories $ 2,499 $ 2,393

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT, AND EQUIPMENT	PROPERTY, PLANT, AND EQUIPMENT Estimated Useful Lives (Years) March 31, 2021 December 31, 2020 In millions Land and land improvements 1 - 25 $ 619 $ 682 Buildings 1 - 50 2,038 2,031 Machinery, equipment, and other 1 - 25 7,211 7,127 Construction in progress 1,235 1,283 Total property, plant and equipment $ 11,103 $ 11,123 Total accumulated depreciation $ 4,359 $ 4,256 Total property, plant and equipment - net $ 6,744 $ 6,867 Three Months Ended March 31, In millions 2021 2020 Depreciation expense $ 161 $ 168

NONCONSOLIDATED AFFILIATES

NONCONSOLIDATED AFFILIATES	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
NONCONSOLIDATED AFFILIATES	NONCONSOLIDATED AFFILIATES The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and other noncurrent receivables" in the interim Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates is shown in the following table: Investments in Nonconsolidated Affiliates March 31, 2021 December 31, 2020 In millions Investments and other noncurrent receivables $ 902 $ 889 Accrued and other current liabilities (69) (71) Net investment in nonconsolidated affiliates $ 833 $ 818 The Company maintained an ownership interest in 14 nonconsolidated affiliates at March 31, 2021.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The changes in the carrying amounts of goodwill during the three months ended March 31, 2021 were as follows: Electronics & Industrial Water & Protection Mobility & Materials Total In millions Balance at December 31, 2020 $ 8,458 $ 6,969 $ 3,275 $ 18,702 Currency Translation Adjustment (61) (88) (50) (199) Other — — 8 8 Balance at March 31, 2021 $ 8,397 $ 6,881 $ 3,233 $ 18,511 The Company tests goodwill for impairment annually during the fourth quarter as of October 1, or more frequently when events or changes in circumstances indicate that fair value is below carrying value. As a result of the related acquisition method of accounting in connection with the DWDP Merger, EID’s assets and liabilities were measured at fair value resulting in increases to the Company’s goodwill and other intangible assets. The fair value valuation increased the risk that declines in financial projections, including changes to key assumptions, could have a material, negative impact on the fair value of the Company’s reporting units and assets, and therefore could result in an impairment. The 2021 Segment Realignment served as a triggering event requiring the Company to perform an impairment analysis related to goodwill carried by its reporting units as of February 1, 2021, prior to the realignment. As part of the 2021 Segment Realignment, the Company assessed and re-defined certain reporting units effective February 1, 2021, including reallocation of goodwill on a relative fair value basis, as applicable, to new reporting units identified. Goodwill impairment analyses were then performed for the new reporting units identified in the Electronics & Industrial and Mobility & Materials segments impacted by the 2021 Segment Realignment. No impairments were identified as a result of the analyses described above. In the first quarter of 2020, expectations of proceeds related to certain potential divestitures within Corporate gave rise to fair value indicators and, thus, served as triggering events requiring the Company to perform impairment analyses related to goodwill. As part of the analysis, the Company determined that the fair value of its Photovoltaic and Advanced Materials (“PVAM”) reporting unit was below its carry value resulting in an impairment charge to goodwill. Valuations of the PVAM reporting unit under a combination of the market approach and income approach reflect softening conditions in photovoltaics markets as compared to prior estimates. In connection with this analysis, the Company recorded a pre-tax, non-cash impairment charge of $533 million for the three months ended March 31, 2020 within Corporate. The Company's analyses above used the discounted cash flow model (a form of the income approach) utilizing Level 3 unobservable inputs. The Company’s significant assumptions in these analyses include, but are not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate, and tax rates. The Company’s estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from the Company’s estimates. If the Company’s ongoing estimates of future cash flows are not met, the Company may have to record additional impairment charges in future periods. As referenced, the Company also uses a form of the market approach. As such, the Company believes the current assumptions and estimates utilized are both reasonable and appropriate. Other Intangible Assets The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2021 December 31, 2020 In millions Gross Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 2,763 $ (1,181) $ 1,582 $ 2,844 $ (1,220) $ 1,624 Trademarks/tradenames 1,095 (453) 642 1,095 (440) 655 Customer-related 6,979 (2,423) 4,556 7,075 (2,361) 4,714 Other 130 (82) 48 131 (81) 50 Total other intangible assets with finite lives $ 10,967 $ (4,139) $ 6,828 $ 11,145 $ (4,102) $ 7,043 Intangible assets with indefinite lives: Trademarks/tradenames 1,029 — 1,029 1,029 — 1,029 Total other intangible assets 1,029 — 1,029 1,029 — 1,029 Total $ 11,996 $ (4,139) $ 7,857 $ 12,174 $ (4,102) $ 8,072 As part of the 2021 Segment Realignment, the Company reallocated its intangible assets with indefinite lives to align with the new segment structure. This served as a triggering event requiring the Company to perform an impairment analysis related to intangible assets with indefinite lives carried by its existing Electronics & Imaging and Transportation & Industrial segments as of February 1, 2021, prior to the realignment. Subsequent to the realignment the Company realigned intangible assets with indefinite lives as applicable to align the intangible assets with indefinite lives with the new segment structure. Impairment analyses were then performed for the intangible assets with indefinite lives carried by the Electronics & Industrial and Mobility & Materials segments. No impairments were identified as a result of the analyses described above. During the first quarter of 2020, the Company recorded non-cash impairment charges related to definite-lived intangible assets impacting Corporate. See Note 4 for further discussion. The following table provides the net carrying value of other intangible assets by segment: Net Intangibles by Segment March 31, 2021 December 31, 2020 In millions Electronics & Industrial $ 2,528 $ 2,611 Water & Protection 2,855 2,920 Mobility & Materials 2,474 2,541 Total $ 7,857 $ 8,072 Total estimated amortization expense for the remainder of 2021 and the five succeeding fiscal years is as follows: Estimated Amortization Expense In millions Remainder of 2021 $ 482 2022 $ 628 2023 $ 603 2024 $ 581 2025 $ 535 2026 $ 516

SHORT TERM BORROWINGS, LONG-TER

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES	SHORT-TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES The Company's long-term debt due within one year at March 31, 2021 and December 31, 2020 was $1,997 million and $1 million, respectively. The following table summarizes the Company's finance lease obligations and long-term debt: Long-Term Debt March 31, 2021 December 31, 2020 In millions Amount Weighted Average Rate Amount Weighted Average Rate Promissory notes and debentures: Final maturity 2021 1 $ 2,000 2.17 % $ — — % Final maturity 2023 2 2,800 3.89 % 4,800 3.18 % Final maturity 2025 2 1,850 4.49 % 1,850 4.49 % Final maturity 2026 and thereafter 2 6,050 5.13 % 6,050 5.13 % Other facilities: Term loan due 2022 — — % 3,000 1.25 % Finance lease obligations 2 2 Less: Unamortized debt discount and issuance costs 80 90 Less: Long-term debt due within one year 1, 3 1,997 1 Total $ 10,625 $ 15,611 1. Represents May 2020 Notes. 2. Represents senior unsecured notes (the "2018 Senior Notes"), which are senior unsecured obligations of the Company. 3. Presented net of current portion of unamortized debt issuance costs. Principal Payments of long-term debt for the remainder of 2021 and the five succeeding fiscal years are as follows: Maturities of Long-Term Debt for Next Five Years at March 31, 2021 Total In millions Remainder of 2021 $ 2,000 2022 $ — 2023 $ 2,800 2024 $ — 2025 $ 1,850 2026 $ — The estimated fair value of the Company's long-term borrowings was determined using Level 2 inputs within the fair value hierarchy, as described in Note 21. Based on quoted market prices for the same or similar issues, or on current rates offered to the Company for debt of the same remaining maturities, the fair value of the Company's long-term borrowings, not including long-term debt due within one year, was $12,617 million and $18,336 million at March 31, 2021 and December 31, 2020, respectively. Available Committed Credit Facilities The following table summarizes the Company's credit facilities: Committed and Available Credit Facilities at March 31, 2021 In millions Effective Date Committed Credit Credit Available Maturity Date Interest Revolving Credit Facility, Five May 2019 $ 3,000 $ 2,978 May 2024 Floating Rate 364-day Revolving Credit Facility April 2020 1,000 1,000 April 2021 Floating Rate Total Committed and Available Credit Facilities $ 4,000 $ 3,978 On April 15, 2021, the Company entered into an updated $1 billion 364-day revolving credit facility (the “2021 $1B Revolving Credit Facility") as the $1 billion 364-day revolving credit facility entered in April 2020 (the “2020 $1B Revolving Credit Facility") expired mid-April. As of the effectiveness of the 2021 $1B Revolving Credit Facility, the 2020 $1B Revolving Credit Facility was terminated. The $1B Revolving Credit facility may be used for general corporate purposes. N&B Transaction As part of the N&B Transaction, the Company received a Special Cash Payment of approximately $7.3 billion. The Special Cash Payment was partially funded by the N&B Notes Offering, which was completed on September 16, 2020. In order to fund the remainder of the Special Cash Payment, immediately prior to the consummation of the N&B Transaction, N&B borrowed $1.25 billion under the N&B Term Loan on February 1, 2021. The obligations and liabilities associated with the N&B Notes Offering and the N&B Term Loan were separated from the Company on February 1, 2021 upon consummation of the N&B Transaction. See Note 2 for more information. May Debt Offering On May 1, 2020, the Company completed an underwritten public offering of senior unsecured notes (the “May 2020 Notes”) in the aggregate principal amount of $2 billion of 2.169 percent fixed rate Notes due May 1, 2023 (the “May Debt Offering”). The consummation of the N&B Transaction triggered the special mandatory redemption feature of the May Debt Offering and on May 3, 2021, the Company provided notice that it will redeem the May 2020 Notes on May 13, 2021. The Company will use proceeds from the Special Cash Payment to redeem the May 2020 Notes in full together with accrued and unpaid interest. Term Loan Facilities On February 1, 2021, the Company terminated its fully drawn term loan facilities in the aggregate principle amount of $3 billion (the "Term Loan Facilities"). The termination triggered the repayment of the aggregate outstanding principal amount of $3 billion, plus accrued and unpaid interest through and including January 31, 2021. The Company funded the repayment with proceeds from the Special Cash Payment. Uncommitted Credit Facilities and Outstanding Letters of Credit Unused bank credit lines on uncommitted credit facilities were $749 million at March 31, 2021. These lines are available to support short-term liquidity needs and general corporate purposes including letters of credit. Outstanding letters of credit were $138 million at March 31, 2021. These letters of credit support commitments made in the ordinary course of business. Debt Covenants and Default Provisions The Company's indenture covenants include customary limitations on liens, sale and leaseback transactions, and mergers and consolidations, subject to certain limitations. The 2018 Senior Notes and May 2020 Notes also contain customary default provisions. The Five-Year Revolving Credit Facility and the 2020 $1B Revolving Credit Facility contain a financial covenant requiring that the ratio of Total Indebtedness to Total Capitalization for the Company and its consolidated subsidiaries not exceed 0.60. At March 31, 2021, the Company was in compliance with this financial covenant. There were no material changes to the debt covenants and default provisions at March 31, 2021.

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	COMMITMENTS AND CONTINGENT LIABILITIES Litigation and Environmental Matters As of March 31, 2021, the Company has liabilities of $18 million associated with litigation matters including non-PFAS liabilities retained, assumed or indemnified under the DWDP Separation and Distribution Agreement discussed below. In addition, DuPont has liabilities of $11 million related to the remaining settlement of the Ohio MDL, discussed below, and of $62 million in connection with the cost sharing arrangement related to future eligible PFAS costs, discussed below, between The Chemours Company (“Chemours”), Corteva, EID and the Company. Management believes that it is reasonably possible the Company could incur eligible PFAS costs in excess of the amounts accrued, but any such losses are not estimable at this time due to various reasons, including, among others, that the underlying matters are in their early stages and have significant factual issues to be resolved. Eligible PFAS costs are included in PFAS Stray Liabilities discussed below. Discontinued and/or Divested Operations and Businesses ("DDOB") Liabilities of EID Under the DWDP Separation and Distribution Agreement and the Letter Agreement between Corteva and DuPont, DDOB liabilities of EID primarily related to EID’s agriculture business were allocated to or retained by Corteva and those primarily related to EID’s specialty products business were allocated to or retained by the Company. EID DDOB liabilities not primarily related to EID’s agriculture business or specialty products business (“Stray Liabilities”), are allocated as follows: • Generally, indemnifiable losses as defined in the DWDP Separation and Distribution Agreement, (“Indemnifiable Losses”) for Stray Liabilities, to the extent they do not arise out of actions related to or resulting from the development, testing, manufacture or sale of PFAS, defined below, (“Non-PFAS Stray Liabilities”) that are known as of April 1, 2019 are borne by Corteva up to a specified amount set forth in the schedules to the Separation and Distribution Agreement and/or Letter Agreement. Non-PFAS Stray Liabilities in excess of such specified amounts and any Non-PFAS Stray Liabilities not listed in the schedules to the DWDP Separation and Distribution Agreement or Letter Agreement are borne by Corteva and/or DuPont up to separate, aggregate thresholds of $200 million each to the extent Corteva or DuPont, as applicable, incurs an Indemnifiable Loss. Once Corteva’s or DuPont’s $200 million threshold is met, the other would generally bear all Non-PFAS Stray Liabilities until meeting its $200 million threshold. After the respective $200 million thresholds are met, DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses. While DuPont believes it is probable that it will incur a liability related to Non-PFAS Stray Liabilities discussed below, such liability is not reasonably estimable at March 31, 2021. Therefore, at March 31, 2021, DuPont has not recorded an accrual related to Non-PFAS Liabilities. • Generally, Corteva and the Company will each bear 50 percent of the first $300 million (up to $150 million each) for Indemnifiable Losses arising out of actions to the extent related to or resulting from the development, testing, manufacture or sale of per- or polyfluoroalkyl substances, which include perfluorooctanoic acids and its ammonium salts (“PFOA”) (all such substances, “PFAS” and such Stray Liabilities referred to as “PFAS Stray Liabilities”), unless either Corteva or DuPont has met its $200 million threshold described above. In that event, the other company would bear all PFAS Stray Liabilities until that company meets its $200 million threshold, at which point DuPont will bear 71 percent of such losses and Corteva will bear 29 percent of such losses. Indemnifiable Losses to the extent related to PFAS Stray Liabilities in excess of $300 million generally will be borne 71 percent by the Company and 29 percent by Corteva. • Indemnifiable Losses incurred by the companies in relation to PFAS Stray Liabilities up to $300 million (e.g., up to $150 million each) will be applied to each company’s respective $200 million threshold. Indemnifiable Losses, as defined in the DWDP Separation and Distribution Agreement, include, among other things, attorneys’, accountants’, consultants’ and other professionals’ fees and expenses incurred in the investigation or defense of Stray Liabilities. DuPont expects to continue to incur directly and as Indemnifiable Losses and/or qualified spend (as defined below), costs and expenses related to litigation defense, such as attorneys’ fees and expenses and court costs, in connection with the Stray Liabilities described below. In accordance with its accounting policy for litigation matters, the Company will expense such litigation defense costs as incurred which could be significant to the Company’s financial condition and/or cash flows in the period. Even when the Company believes the probability of loss or of an adverse unappealable final judgment is remote, the Company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the Company, including avoidance of future distraction and litigation defense cost, and its shareholders. PFAS Stray Liabilities: Future Eligible PFAS Costs On July 1, 2015, EID completed the separation of EID’s Performance Chemicals segment through the spin-off of Chemours to holders of EID common stock (the “Chemours Separation”). In connection with the spin-off, EID and Chemours entered into a Separation Agreement. In 2017, EID and Chemours amended the Chemours Separation Agreement (as amended, the “Chemours Separation Agreement”) to provide for a limited sharing of potential future liabilities related to alleged historical releases of PFOA for a five-year period that began on July 6, 2017. On January 22, 2021, the Company, Corteva, EID and Chemours entered into a binding Memorandum of Understanding (the “MOU”), pursuant to which the parties have agreed to release certain claims that had been raised by Chemours including any claims arising out of or resulting from the process and manner in which EID structured or conducted the Chemours Separation, and any other claims that challenge the Chemours Separation or the assumption of Chemours Liabilities (as defined in the Chemours Separation Agreement) by Chemours and the allocation thereof, subject in each case to certain exceptions set forth in the MOU. In connection with the MOU, the confidential arbitration process regarding certain claims by Chemours was terminated in February 2021. The parties have further agreed not to bring any future, additional claims regarding the Chemours Separation Agreement or the MOU outside of arbitration. Pursuant to the MOU, the parties have agreed to share certain costs associated with potential future liabilities related to alleged historical releases of certain PFAS, including PFOA, out of pre-July 1, 2015 conduct (“eligible PFAS costs”) until the earlier to occur of (i) December 31, 2040, (ii) the day on which the aggregate amount of qualified spend (as defined in the MOU) is equal to $4 billion or (iii) a termination in accordance with the terms of the MOU. This sharing arrangement replaces the cost sharing arrangement between EID and Chemours established pursuant to the Chemours Separation Agreement. The parties have agreed that, during the term of this sharing arrangement, Chemours will bear 50 percent of any qualified spend and the Company and Corteva shall bear 50 percent of any qualified spend. The Company’s and Corteva’s share of qualified spend shall not exceed $2 billion in the aggregate. After the term of this arrangement, Chemours’ indemnification obligations under the Chemours Separation Agreement would continue unchanged, subject in each case to certain exceptions set forth in the MOU. In order to support and manage any potential future eligible PFAS costs, the parties have also agreed to establish an escrow account. The MOU provides that (1) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 million into an escrow account and DuPont and Corteva shall together deposit $100 million in the aggregate into an escrow account and (2) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 million into an escrow account and DuPont and Corteva shall together deposit $50 million in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700 million, Chemours will make 50 percent of the deposits and DuPont and Corteva together will make 50 percent of the deposits necessary to restore the balance of the escrow account to $700 million. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU. All funding obligations of the Company and Corteva under this sharing arrangement, whether in respect of escrow funding or in respect of qualified spend, will be allocated between the Company and Corteva in accordance with the terms of the DWDP Separation and Distribution Agreement and the terms of the Letter Agreement. Future charges, if any, associated with the MOU would be recognized over the term of the agreement as a component of income from discontinued operations to the extent liabilities become probable and estimable. The parties have agreed to cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU in the second quarter of 2021. Ohio MDL Personal Injury Cases DuPont, which was formed after the spin-off of Chemours by EID, is not named in the personal injury and other PFAS actions discussed below. In 2004, EID settled a West Virginia state court class action, Leach v. DuPont, which alleged that PFOA from EID’s former Washington Works facility had contaminated area drinking water supplies and affected the health of area residents. Members of the Leach class have standing to pursue personal injury claims for just six health conditions that an expert panel appointed under the Leach settlement reported in 2012 had a “probable link” (as defined in the settlement) with PFOA: pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol. In 2017, Chemours and EID each paid $335 million to settle the multi-district litigation in the U.S. District Court for the Southern District of Ohio (“Ohio MDL”), thereby resolving claims of about 3,550 plaintiffs alleging injury from exposure to PFOA in drinking water. The 2017 settlement did not resolve claims of Leach class members who did not have claims in the Ohio MDL or whose claims are based on diseases first diagnosed after February 11, 2017. Since the 2017 settlement about 100 additional cases alleging personal injury, including kidney and testicular cancer claims, have been filed or noticed and are pending in the Ohio MDL. On January 21, 2021, EID and Chemours entered into settlement agreements with plaintiffs’ counsel representing the Ohio MDL plaintiffs providing for a settlement of cases and claims in the Ohio MDL, except as noted below (the “Settlement”). The total settlement amount is $83 million in cash with each of the Company and EID contributing $27 million and Chemours contributing $29 million. At March 31, 2021 the Company had paid $16 million of its $27 million contribution; the remainder was paid in April 2021. T he Settlement was entered into solely by way of compromise and settlement and is not in any way an admission of liability or fault by the Company, Corteva, EID or Chemours. In connection with the Settlement, in April 2021 the plaintiffs filed a motion to terminate the Ohio MDL. The case captioned “Abbott v E. I. du Pont de Nemours and Company” is not included in the Settlement and is presently pending appeal. In the Abbott case, the jury returned a verdict in March 2020 against EID, awarding $50 million in compensatory damages to the plaintiff and his wife, who claimed that exposure to PFOA in drinking water caused him to develop testicular cancer. In March 2021, the trial judge entered an order denying EID’s post-trial motions for a reduction in the verdict amount for Mr. Abbott but reduced Mrs. Abbott’s verdict for loss of consortium from $10 million to $250,000, reducing the total verdict to $40.25 million. EID has appealed the verdict. The plaintiffs also sought but were not awarded punitive damages. In addition to the actions described above, there are several cases alleging damages to natural resources, the environment, water, and/or property as well as various other allegations. DuPont and Corteva are named in most of the actions discussed below. Such actions include additional claims based on allegations that the transfer by EID of certain PFAS liabilities to Chemours prior to the Chemours Separation resulted in a fraudulent conveyance or voidable transaction. With the exception of the fraudulent conveyance claims, which are excluded from the MOU, legal fees, expenses, costs, and any potential liabilities for eligible PFAS costs presented by the following matters will be shared as defined in the MOU between Chemours, EID, Corteva and DuPont. Natural Resource Damage Matters Since May 2017, a number of state attorneys general have filed lawsuits against DuPont, Corteva, EID, Chemours, and others, claiming environmental contamination by certain PFAS compounds. Such actions are currently pending in Michigan, New Hampshire, New Jersey, North Carolina, Ohio and Vermont. Generally, the states raise common law tort claims and seek economic impact damages for alleged harm to natural resources, punitive damages, present and future costs to cleanup contamination from certain PFAS compounds, and to abate the alleged nuisance. Most of these actions include fraudulent transfer claims related to the Chemours Separation and the DowDuPont separations. Additionally, DuPont has engaged with the State of Delaware regarding potential similar causes of action for PFAS and other contaminants. Other PFAS Environmental Matters Several additional lawsuits have been filed by residents, local water districts, and private water companies against EID, Chemours, Corteva, DuPont and others in New York, New Jersey, and California generally alleging contamination of water systems due to the release of PFAS compounds. These suits seek compensatory and punitive damages, as well as present and future costs to clean up the alleged contamination. This includes a putative class action filed in the Northern District of New York on behalf of all individuals who, as of December 1, 2015, are or were owners of real property located in the Village of Hoosick Falls, New York and who obtain their drinking water from a privately owned well which has allegedly been contaminated by PFAS. The plaintiffs seek compensatory and punitive damages as well as medical monitoring. The certification of the class is currently pending before the court. Additionally, there are several actions that have been filed in New Jersey and New York on behalf of residents who allege personal injuries due to exposure to PFAS in their drinking water. These lawsuits generally seek compensatory and punitive damages stemming from those alleged injuries and medical monitoring. Aqueous Film Forming Foam Beginning in April 2019, several dozen lawsuits involving water contamination arising from the use of PFAS-containing aqueous firefighting foams (“AFFF”) were filed against EID, Chemours, 3M and other AFFF manufacturers and in different parts of the country. Most were consolidated in multi-district litigation docket in federal district court in South Carolina (the “SC MDL”). Many of those cases also name DuPont as a defendant. Those actions largely seek remediation of the alleged PFAS contamination in and around military bases and airports as well as medical monitoring of affected residents. The first ten bellwether cases have been selected by the court, all of which are water district contamination cases. As of March 31, 2021, approximately 1,020 personal injury cases have been filed directly in the SC MDL and assert claims on behalf of individual firefighters and others who allege that exposure to PFAS in firefighting foam caused them to develop cancer, including kidney and testicular cancer. DuPont has been named as a defendant in most of these personal injury AFFF cases. DuPont is seeking the dismissal of DowDuPont and DuPont from these actions. EID and the Company have never made or sold AFFF, perfluorooctanesulfonic acid ("PFOS") or PFOS containing products. Additionally, a case filed by a former firefighter is pending in the Southern District of Ohio seeking certification of a nationwide class of individuals who have detectable levels of PFAS in their blood serum. The suit was filed against 3M and several other defendants in addition to Chemours and EID. The complaint specifically seeks, among other things, the creation of a “PFAS Science Panel” to study the effects of PFAS, but expressly states that the class does not seek compensatory damages for personal injuries. In February 2020, the court denied the defendants' motion to transfer this case to the SC MDL. The decision of whether to certify the class is currently pending before the court. North Carolina PFAS Actions There are several actions pending in federal court against EID and Chemours, relating to discharges of PFCs, including GenX, into the Cape Fear River. GenX is a polymerization processing aid and a replacement for PFOA introduced by EID which Chemours continues to manufacture at its Fayetteville Works facility in Bladen County, North Carolina. One of these actions is a consolidated putative class action that asserts claims for damages and other relief on behalf of putative classes of property owners and residents in areas near or who draw drinking water from the Cape Fear River. Another action is a consolidated action brought by various North Carolina water authorities, including the Cape Fear Public Utility Authority and Brunswick County, that seek actual and punitive damages as well as injunctive relief. In addition, an action is pending in North Carolina state court on behalf of about 200 plaintiffs who own wells and property near the Fayetteville Works facility. The plaintiffs seek damages for nuisance allegedly caused by releases of certain PFCs from the site. In the third quarter 2020, three lawsuits were filed in North Carolina state court against Chemours, EID, Corteva and DuPont. The lawsuits seek damages for alleged personal injuries to more than 100 individuals due to alleged exposure to PFOA and GenX originating from the Fayetteville Works plant. These lawsuits also include fraudulent transfer allegations related to the Chemours Separation. Other Litigation Matters In addition to the specific matters described above, the Company is party to other claims and lawsuits arising out of the normal course of business with respect to product liability, patent infringement, governmental regulation, contract and commercial litigation, and other actions. Certain of these actions may purport to be class actions and seek damages in very large amounts. It is the opinion of the Company’s management that the possibility is remote that the aggregate of all such other claims and lawsuits will have a material adverse impact on the results of operations, financial condition and cash flows of the Company. Environmental Matters Accruals for environmental matters are recorded when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on current law and existing technologies. At March 31, 2021, the Company had accrued obligations of $82 million for probable environmental remediation and restoration costs, inclusive of $37 million retained and assumed following the DWDP Distributions and $45 million of indemnified liabilities. These obligations are included in "Accrued and other current liabilities" and "Other noncurrent obligations" in the Consolidated Balance Sheets. This is management’s best estimate of the costs for remediation and restoration with respect to environmental matters for which the Company has accrued liabilities, although it is reasonably possible that the ultimate cost with respect to these particular matters could range up to $172 million above the amount accrued at March 31, 2021. Consequently, it is reasonably possible that environmental remediation and restoration costs in excess of amounts accrued could have a material impact on the Company’s results of operations, financial condition and cash flows. Inherent uncertainties exist in these estimates primarily due to unknown conditions, changing governmental regulations and legal standards regarding liability, and emerging remediation technologies for handling site remediation and restoration. At December 31, 2020 the Company had accrued obligations of $80 million for probable environmental remediation and restoration costs. Pursuant to the DWDP Separation and Distribution Agreement, the Company is required to indemnify certain clean-up responsibilities and associated remediation costs. The accrued environmental obligations of $45 million as of March 31, 2021 includes amount for which the Company indemnifies Dow and Corteva. At March 31, 2021, the Company has indemnified Dow and Corteva $8 million and $37 million, respectively. Indemnifications In connection with the ongoing divestitures and transactions, the Company has indemnified and has been indemnified by respective parties against certain liabilities that may arise in connection with these transactions and business activities prior to the completion of the respective transactions. The term of these indemnifications, which typically pertain to environmental, tax and product liabilities, is generally indefinite. At March 31, 2021, the indemnification assets were $80 million within "Accounts and notes receivable - net" and $228 million within "Deferred charges and other assets" and the indemnification liabilities were $160 million within "Accrued and other current liabilities" and $140 million within "Other noncurrent obligations" within the Consolidated Balance Sheets. Guarantees Obligations for Equity Affiliates & Others The Company has directly guaranteed various debt obligations under agreements with third parties related to equity affiliates and customers. At March 31, 2021 and December 31, 2020, the Company had directly guaranteed $180 million and $189 million, respectively, of such obligations. These amounts represent the maximum potential amount of future (undiscounted) payments that the Company could be required to make under the guarantees. The Company would be required to perform on these guarantees in the event of default by the guaranteed party. The Company assesses the payment/performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used. In certain cases, the Company has recourse to assets held as collateral, as well as personal guarantees from customers. At March 31, 2021, no collateral was held by the Company. The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee: Guarantees at March 31, 2021 Final Expiration Year Maximum Future Payments In millions Obligations for customers 1 : Bank borrowings 2021 $ 15 Obligations for non-consolidated affiliates 2 : Bank borrowings 2021 $ 165 Total guarantees $ 180 1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At March 31, 2021, all maximum future payments had terms less than a year. 2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

OPERATING LEASES

OPERATING LEASES	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
OPERATING LEASES	OPERATING LEASES Operating lease costs for the three months ended March 31, 2021 and 2020 were $29 million and $31 million, respectively. Operating cash flows from operating leases were $29 million and $31 million for the three months ended March 31, 2021 and 2020, respectively. Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. New operating lease assets and liabilities entered into during the three months ended March 31, 2021 and 2020 were $22 million and $53 million, respectively. Supplemental balance sheet information related to leases was as follows: In millions March 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets 1 $ 416 $ 423 Current operating lease liabilities 2 98 117 Noncurrent operating lease liabilities 3 320 308 Total operating lease liabilities $ 418 $ 425 1. Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet. 3. Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet. Operating lease right-of-use assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As most of the Company’s leases do not provide the lessor’s implicit rate, the Company uses its incremental borrowing rate at the commencement date in determining the present value of lease payments. Lease Term and Discount Rate for Operating Leases March 31, 2021 December 31, 2020 Weighted-average remaining lease term (years) 7.63 6.78 Weighted average discount rate 2.06 % 2.41 % Maturities of lease liabilities were as follows: Maturity of Lease Liabilities at March 31, 2021 Operating Leases In millions Remainder of 2021 $ 83 2022 91 2023 70 2024 51 2025 30 2026 and thereafter 133 Total lease payments $ 458 Less: Interest 40 Present value of lease liabilities $ 418

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS' EQUITY As part of the Exchange Offer from the N&B Transaction, the Company accepted and retired approximately 197.4 million shares of its common stock in exchange for about 141.7 million shares of N&B Common Stock. As a result, the Company reduced its common stock outstanding by 197.4 million shares of DuPont Common Stock as of February 1, 2021. Share Repurchase Program On June 1, 2019, the Company's Board of Directors approved a $2 billion share buyback program ("2019 Share Buyback Program"), which expires on June 1, 2021. During the first quarter, the Company repurchased and retired 6.8 million shares for $500 million under the 2019 Share Buyback Program. At March 31, 2021, the Company had repurchased and retired a total of 23.7 million shares at a cost of $1.5 billion. In the first quarter of 2021, the Company's Board of Directors authorized a new $1.5 billion share buyback program, which expires on June 30, 2022 ("2021 Share Buyback Program"). The Company expects to repurchase shares under the 2021 Share Buyback Program after the completion of the 2019 Share Buyback Program. Accumulated Other Comprehensive Loss The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2021 and 2020: Accumulated Other Comprehensive Loss Cumulative Translation Adj Pension and OPEB Derivative Instruments Total In millions 2020 Balance at January 1, 2020 $ (1,070) $ (345) $ (1) $ (1,416) Other comprehensive loss before reclassifications (396) (2) — (398) Amounts reclassified from accumulated other comprehensive loss — 4 — 4 Net other comprehensive income (loss) $ (396) $ 2 $ — $ (394) Balance at March 31, 2020 $ (1,466) $ (343) $ (1) $ (1,810) 2021 Balance at January 1, 2021 $ 470 $ (425) $ (1) $ 44 Other comprehensive (loss) income before reclassifications (477) 8 — (469) Amounts reclassified from accumulated other comprehensive loss — 4 — 4 Split-off of N&B reclassification adjustment 184 73 1 258 Net other comprehensive (loss) income $ (293) $ 85 $ 1 $ (207) Balance at March 31, 2021 $ 177 $ (340) $ — $ (163) The tax effects on the net activity related to each component of other comprehensive income (loss) were not material for the three months ended March 31, 2021 and 2020. A summary of the reclassifications out of AOCL for the three months ended March 31, 2021 and 2020 is provided as follows: Reclassifications Out of Accumulated Other Comprehensive Loss Three Months Ended Income Classification In millions 2021 2020 Cumulative translation adjustments $ 184 $ — See (1) below Pension and other post-employment benefit plans $ 106 $ 3 See (1) below Tax (benefit) expense (29) 1 See (1) below After tax $ 77 $ 4 Derivative Instruments $ 1 $ — See (1) below Total reclassifications for the period, after tax $ 262 $ 4 1. The activity for the three months ended March 31, 2021 is classified within "Income (loss) from discontinued operations, net of tax" and "Sundry income (expense) - net" as part of the N&B Transaction and continuing operations, respectively. The activity for the three months ended March 31, 2020 is classified within the "Sundry income (expense) - net" and "Provision for income taxes on continuing operations" lines.

NONCONTROLLING INTERESTS

NONCONTROLLING INTERESTS	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
NONCONTROLLING INTERESTS	NONCONTROLLING INTERESTS Ownership interests in the Company's subsidiaries held by parties other than the Company are presented separately from the Company's equity in the interim Condensed Consolidated Balance Sheets as "Noncontrolling interests." The amounts of consolidated net income attributable to the Company and the noncontrolling interests are both presented on the face of the interim Consolidated Statements of Operations. The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2021 and 2020: Noncontrolling Interests Three Months Ended March 31, In millions 2021 2020 Balance at beginning of period $ 566 $ 569 Net income attributable to noncontrolling interests 4 6 Distributions to noncontrolling interests (19) (6) Cumulative translation adjustments (7) (8) Split-off of N&B (27) — Other — 5 Balance at end of period $ 517 $ 566

PENSION PLANS AND OTHER POST-EM

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS	3 Months Ended
	Mar. 31, 2021
Retirement Benefits [Abstract]
PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS	PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS A summary of the Company's pension plans and other post-employment benefits can be found in Note 19 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. On February 1, 2021, the Company's net underfunded balance was reduced by $232 million after certain assets and obligations were separated from the Company to N&B plans effective as part of the N&B Transaction. The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans: Net Periodic Benefit (Credit) Cost for All Plans Three Months Ended March 31, In millions 2021 2020 Defined Benefit Pension Plans: Service cost 1 $ 15 $ 18 Interest cost 2 11 14 Expected return on plan assets 3 (28) (28) Amortization of prior service credit 4 (1) (1) Amortization of net loss 5 3 4 Curtailment/settlement 6 2 — Net periodic benefit cost - total $ 2 $ 7 Less: Net periodic benefit cost - discontinued operations 1 4 Net periodic benefit cost - continuing operations $ 1 $ 3 1. The service cost from continuing operations was $13 million and $14 million for the three months ended March 31, 2021 and 2020, respectively. 2. The interest cost from continuing operations was $11 million and $13 million for the three months ended March 31, 2021 and 2020, respectively. 3. The expected return on plan assets from continuing operations was $27 million and $26 million for the three months ended March 31, 2021 and 2020, respectively. 4. The amortization of prior service credit from continuing operations a gain of $1 million for both the three months ended March 31, 2021 and 2020. 5. The amortization of unrecognized net loss from continuing operations was $3 million for both the three months ended March 31, 2021 and 2020. 6. The curtailment and settlement costs from continuing operations was $2 million for the three months ended March 31, 2021. There were no curtailment or settlement costs from continuing operations for the three months ended March 31, 2020. Activity related to other post-employment benefits was considered immaterial for both the current and comparative periods. The continuing operations portion of the net periodic benefit (credit) cost, other than the service cost component, is included in "Sundry income (expense) - net" in the interim Consolidated Statements of Operations. DuPont expects to make additional contributions in the aggregate of approximately $75 million by year-end 2021.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION A summary of the Company's stock-based compensation plans can be found in Note 20 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. In the second quarter of 2020, the stockholders of DuPont approved the 2020 Equity and Incentive Plan (the "2020 Plan") which allows the Company to grant options, share appreciation rights, restricted shares, restricted stock units ("RSUs"), share bonuses, other share-based awards, cash awards, or a combination of the foregoing. Under the 2020 Plan, a maximum of 18 million shares of common stock are available for award as of March 31, 2021. In June of 2019, DuPont adopted the DuPont Omnibus Incentive Plan ("DuPont OIP") which provides for equity-based and cash incentive awards to certain employees, directors, independent contractors and consultants in the form of stock options, RSUs and performance-based restricted stock units ("PSUs"). Under the DuPont OIP, a maximum of 2 million shares of common stock are available for award as of March 31, 2021. DuPont recognized share-based compensation expense in continuing operations of $17 million and $38 million for the three months ended March 31, 2021 and 2020, respectively. The income tax benefits related to stock-based compensation arrangements were $3 million and $8 million for the three months ended March 31, 2021 and 2020, respectively. In the first quarter of 2021, the Company granted 0.6 million RSUs, 0.6 million stock options and 0.4 million PSUs. The weighted-average fair values per share associated with the grants were $72.88 per RSU, $16.92 per stock option and $78.23 per PSU. The stock options had a weighted-average exercise price per share of $72.98. Effect of the N&B Distributions on Equity Awards At the time of the N&B Distribution, outstanding, unvested share-based compensation awards that were denominated in DuPont common stock and held by N&B Employees were terminated and reissued as equity awards issued under the IFF stock plan.

FINANCIAL INSTRUMENTS

FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2021
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS	FINANCIAL INSTRUMENTS The following table summarizes the fair value of financial instruments at March 31, 2021 and December 31, 2020: Fair Value of Financial Instruments March 31, 2021 December 31, 2020 In millions Cost Gain Loss Fair Value Cost Gain Loss Fair Value Cash equivalents $ 3,246 $ — $ — $ 3,246 $ 1,105 $ — $ — $ 1,105 Restricted cash equivalents 1 $ 14 $ — $ — $ 14 $ 6,223 $ — $ — $ 6,223 Marketable securities $ 2,001 $ — $ — $ 2,001 $ — $ — $ — $ — Total cash equivalents, restricted cash equivalents and marketable securities $ 5,261 $ — $ — $ 5,261 $ 7,328 $ — $ — $ 7,328 Long-term debt including debt due within one year $ (12,622) $ — $ (2,002) $ (14,624) $ (15,612) $ — $ (2,725) $ (18,337) Derivatives relating to: Foreign currency 2 — 13 (10) 3 — 4 (13) (9) Total derivatives $ — $ 13 $ (10) $ 3 $ — $ 4 $ (13) $ (9) 1. Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets. 2. Presented net of cash collateral where master netting arrangements allow. Derivative Instruments Objectives and Strategies for Holding Derivative Instruments In the ordinary course of business, the Company enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency, and interest rate risks. The Company has established a variety of derivative programs to be utilized for financial risk management. These programs reflect varying levels of exposure coverage and time horizons based on an assessment of risk. Derivative programs have procedures and controls and are approved by the Corporate Financial Risk Management Committee, consistent with the Company's financial risk management policies and guidelines. Derivative instruments used are forwards, options, futures and swaps. As of the first quarter of 2021, the Company has not designated any derivatives or non-derivatives as hedging instruments. The Company's financial risk management procedures also address counterparty credit approval, limits and routine exposure monitoring and reporting. The counterparties to these contractual arrangements are major financial institutions and major commodity exchanges. The Company is exposed to credit loss in the event of nonperformance by these counterparties. The Company utilizes collateral support annex agreements with certain counterparties to limit its exposure to credit losses. The Company anticipates performance by counterparties to these contracts and therefore no material loss is expected. Market and counterparty credit risks associated with these instruments are regularly reported to management. The notional amounts of the Company's derivative instruments were as follows: Notional Amounts March 31, 2021 Dec 31, 2020 In millions Derivatives not designated as hedging instruments: Foreign currency contracts 1 $ 84 $ (304) 1. Presented net of contracts bought and sold. Derivatives not Designated in Hedging Relationships Foreign Currency Contracts The Company routinely uses forward exchange contracts to reduce its net exposure, by currency, related to foreign currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. The netting of such exposures precludes the use of hedge accounting; however, the required revaluation of the forward contracts and the associated foreign currency-denominated monetary assets and liabilities intends to achieve a minimal earnings impact, after taxes. The Company may use foreign currency exchange contracts to offset a portion of the Company's exposure to certain foreign currency-denominated revenues so that gains and losses on the contracts offset changes in the USD value of the related foreign currency-denominated revenues. Effect of Derivative Instruments Foreign currency derivatives not designated as hedges are used to offset foreign exchange gains or losses resulting from the underlying exposures of foreign currency-denominated assets and liabilities. The amount charged on a pre-tax basis related to foreign currency derivatives not designated as a hedge, which was included in “Sundry income (expense) - net” in the interim Consolidated Statements of Operations, was a loss of $20 million for the three months ended March 31, 2021 ($4 million gain for the month ended March 31, 2020). The income statement effects of other derivatives were immaterial. Reclassification from AOCL The Company does not expect to reclassify gains or losses related to foreign currency contracts from AOCL to income within the next 12 months and there are currently no such amounts included within AOCL.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Fair Value Measurements on a Recurring Basis The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis: Basis of Fair Value Measurements on a Recurring Basis at March 31, 2021 Significant Other Observable Inputs In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 3,260 Marketable securities 2 2,001 Derivatives relating to: 3 Foreign currency contracts 4 20 Total assets at fair value $ 5,281 Liabilities at fair value: Long-term debt including debt due within one year 5 $ 14,624 Derivatives relating to: 3 Foreign currency contracts 4 17 Total liabilities at fair value $ 14,641 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. Primarily time deposits with maturities of greater than three months at time of acquisition. 3. See Note 20 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 4. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $7 million for both assets and liabilities as of March 31, 2021. 5. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Basis of Fair Value Measurements on a Recurring Basis at December 31, 2020 Significant Other Observable Inputs In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 7,328 Derivatives relating to: 2 Foreign currency contracts 3 13 Total assets at fair value $ 7,341 Liabilities at fair value: Long-term debt including debt due within one year 4 $ 18,337 Derivatives relating to: 2 Foreign currency contracts 3 22 Total liabilities at fair value $ 18,359 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 20 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $9 million for both assets and liabilities as of December 31, 2020. 4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. 2020 Fair Value Measurements on a Nonrecurring Basis During the first quarter of 2020, the Company recorded impairment charges related to long-lived assets within the Biomaterials business unit. See Note 4 for further discussion of this fair value measurement.

SEGMENTS AND GEOGRAPHIC REGIONS

SEGMENTS AND GEOGRAPHIC REGIONS	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
SEGMENTS AND GEOGRAPHIC REGIONS	SEGMENTS AND GEOGRAPHIC REGIONS The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., “Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / OPEB benefits / charges, and foreign exchange gains / losses, adjusted for significant items. Reconciliations of these measures are provided on the following pages. Effective February 1, 2021, in conjunction with the closing of the N&B Transaction, the Company completed the 2021 Segment Realignment resulting in a change to its management and reporting structure. These changes resulted in the following: • Realignment of certain businesses from Transportation & Industrial to Electronics & Imaging • Dissolution of the Non-Core segment with the businesses to be divested and previously divested reflected in Corporate • Realignment of the remaining Non-Core businesses to Transportation & Industrial In addition, the following name changes occurred: • Electronics & Imaging was renamed Electronics & Industrial • Transportation & Industrial was renamed Mobility & Materials • Safety & Construction was renamed Water & Protection The reporting changes have been retrospectively reflected in the segment results for all periods presented. Segment Information Elect. & Industrial Water & Protection Mobility & Materials Corporate 1 Total In millions Three Months Ended March 31, 2021 Net sales $ 1,300 $ 1,328 $ 1,215 $ 133 $ 3,976 Operating EBITDA 2 $ 436 $ 355 $ 278 $ (22) $ 1,047 Equity in earnings of nonconsolidated affiliates $ 9 $ 12 $ 3 $ 2 $ 26 Three months ended March 31, 2020 Net sales $ 1,115 $ 1,276 $ 1,091 $ 188 $ 3,670 Operating EBITDA 2 $ 327 $ 357 $ 215 $ 8 $ 907 Equity in earnings of nonconsolidated affiliates $ 9 $ 7 $ 1 $ 22 $ 39 1. Corporate includes activity of to be divested and previously divested businesses. 2. A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA is provided below. Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended March 31, 2021 and 2020 Three Months Ended March 31, In millions 2021 2020 Income (Loss) from continuing operations, net of tax $ 541 $ (550) + Provision for income taxes on continuing operations 32 94 Income (Loss) from continuing operations before income taxes $ 573 $ (456) + Depreciation and amortization 328 345 - Interest income 1 2 2 + Interest expense 146 171 - Non-operating pension/OPEB benefit 1 12 11 - Foreign exchange losses, net 1 (9) (3) - Significant items (5) (857) Operating EBITDA $ 1,047 $ 907 1. Included in "Sundry income (expense) - net." The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above: Significant Items by Segment for the Three Months Ended March 31, 2021 Elect. & Industrial Water & Protection Mobility & Materials Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ (6) $ (6) Restructuring and asset related charges - net 2 — — — (2) (2) Gain on divestiture 3 2 — — 1 3 Total $ 2 $ — $ — $ (7) $ (5) 1. Integration and separation costs related to strategic initiatives including the divestiture of the Held for Sale Disposal Group. 2. Includes Board approved restructuring plans and asset related charges. See Note 4 for additional information. 3. Reflected in "Sundry income (expense) - net." Significant Items by Segment for the Three Months Ended March 31, 2020 Elect. & Industrial Water & Protection Mobility & Materials Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ (123) $ (123) Restructuring and asset related charges - net 2 (4) (25) (25) (74) (128) Goodwill impairment charge 3 — — — (533) (533) Asset impairment charges 4 — — — (270) (270) Gain on divestiture 5 197 — — — 197 Total $ 193 $ (25) $ (25) $ (1,000) $ (857) 1. Integration and separation costs related to the post-DWDP Merger integration and the DWDP Distributions. 2. Includes Board approved restructuring plans and asset related charges. See Note 4 for additional information. 3. See Note 12 for additional information. 4. See Note 4 for additional information. 5. Reflected in "Sundry income (expense) - net." See Note 2 for additional information.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Interim Financial Statements and Basis of Presentation	Interim Financial Statements The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the interim statements reflect all adjustments (including normal recurring accruals) which are considered necessary for the fair statement of the results for the periods presented. Results from interim periods should not be considered indicative of results for the full year. These interim Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, collectively referred to as the “2020 Annual Report.” The interim Consolidated Financial Statements include the accounts of the Company and all of its subsidiaries in which a controlling interest is maintained.
N&B Transaction	Basis of Presentation Effective August 31, 2017, pursuant to the merger of equals transaction contemplated by the Agreement and Plan of Merger, dated as of December 11, 2015, as amended on March 31, 2017 ("Merger Agreement"), The Dow Chemical Company ("TDCC") and E. I. du Pont de Nemours and Company ("EID") each merged with subsidiaries of DowDuPont Inc. ("DowDuPont") and, as a result, TDCC and EID became subsidiaries of DowDuPont (the "DWDP Merger"). Except as otherwise indicated by the context, the term "TDCC" includes TDCC and its consolidated subsidiaries and "EID" includes EID and its consolidated subsidiaries. On April 1, 2019, the Company completed the separation of the materials science business through the spin-off of Dow Inc., (“Dow”) including Dow’s subsidiary TDCC (the “Dow Distribution”). On June 1, 2019, the Company completed the separation of the agriculture business through the spin-off of Corteva, Inc. (“Corteva”) including Corteva’s subsidiary EID, (the “Corteva Distribution" and together with the Dow Distribution, the “DWDP Distributions”). Following the Corteva Distribution, DuPont holds the specialty products business as continuing operations. On June 1, 2019, DowDuPont changed its registered name from "DowDuPont Inc." to "DuPont de Nemours, Inc." doing business as "DuPont." Beginning on June 3, 2019, the Company's common stock is traded on the NYSE under the ticker symbol "DD." N&B Transaction On February 1, 2021, DuPont completed the separation and distribution of the Nutrition & Biosciences business segment (the "N&B Business"), and merger of Nutrition & Biosciences, Inc. (“N&B”), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF"). The distribution was effected through an exchange offer (the “Exchange Offer”) and the consummation of the Exchange Offer was followed by the merger of N&B with a wholly owned subsidiary of IFF, with N&B surviving the merger as a wholly owned subsidiary of IFF (the “N&B Merger” and, together with the Exchange Offer, the “N&B Transaction”). See Note 2 for more information. The financial position of DuPont as of March 31, 2021 and December 31, 2020 and the results of operations of DuPont for the three months ended March 31, 2021 and 2020 present the historical financial results of N&B as discontinued operations. The cash flows and comprehensive income related to N&B have not been segregated and are included in the interim Consolidated Statements of Cash Flows and interim Consolidated Statements of Comprehensive Income, respectively, for all periods presented. Unless otherwise indicated, the information in the notes to the interim Consolidated Financial Statements refer only to DuPont's continuing operations and do not include discussion of balances or activity of N&B. 2021 Segment Realignment Immediately following the separation and distribution of the N&B Business, the Company made changes to its management and reporting structure (the “2021 Segment Realignment”) (see Note 22 for additional details). The reporting changes have been retrospectively reflected for all periods presented.

ACQUISITIONS AND DIVESTITURES (

ACQUISITIONS AND DIVESTITURES (Tables)	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Schedule of Disposal Groups, Including Discontinued Operations	The results of operations of N&B are presented as discontinued operations as summarized below: Three Months Ended March 31, 2021 Three Months Ended In millions Net sales $ 507 $ 1,551 Cost of sales 352 999 Research and development expenses 21 63 Selling, general and administrative expenses 44 151 Amortization of intangibles 38 355 Restructuring and asset related charges - net 1 6 Integration and separation costs 149 74 Sundry income (expense) - net (2) (1) Interest expense 13 12 Loss from discontinued operations before income taxes (113) (110) Benefit from income taxes on discontinued operations (21) (50) Loss from discontinued operations, net of tax (92) (60) Non-taxable gain on split-off 4,954 — Income (loss) from discontinued operations attributable to DuPont stockholders, net of tax $ 4,862 $ (60) The following table presents depreciation, amortization, and capital expenditures of the discontinued operations related to N&B: Three Months Ended March 31, 2021 Three Months Ended In millions Depreciation and amortization $ 63 $ 427 Capital expenditures $ 27 $ 92 The carrying amount of major classes of assets and liabilities that were included in discontinued operations at December 31, 2020 related to N&B consist of the following: In millions December 31, 2020 Assets Accounts and notes receivable - net $ 1,130 Inventories 1,333 Other current assets 65 Investments and noncurrent receivables 36 Property, plant, and equipment - net 3,118 Goodwill 11,542 Other intangible assets - net 3,072 Deferred income tax assets 44 Deferred charges and other assets 319 Total assets of discontinued operations $ 20,659 Liabilities Short-term borrowings and finance lease obligations $ 4 Accounts Payable 742 Income taxes payable 36 Accrued and other current liabilities 301 Long-term debt 6,195 Deferred income tax liabilities 852 Pension and other post employment benefits - noncurrent 238 Other noncurrent obligations 242 Total liabilities of discontinued operations $ 8,610 In millions March 31, 2021 December 31, 2020 Assets Accounts and notes receivable - net $ 68 $ 63 Inventories 72 75 Other current assets 36 35 Investments and noncurrent receivables 166 164 Property, plant and equipment - net 83 34 Goodwill 267 267 Other intangible assets 168 168 Deferred charges and other assets 3 4 Assets held for sale $ 863 $ 810 Liabilities Accounts payable $ 44 $ 40 Income taxes payable 3 1 Accrued and other current liabilities 40 50 Deferred income tax liabilities 29 30 Pension and other post-employment benefits - noncurrent 1 1 Other noncurrent obligations 16 18 Liabilities related to assets held for sale $ 133 $ 140
Schedule of Integration and Separation Costs	Three Months Ended March 31, In millions 2021 2020 Integration and separation costs $ 6 $ 123

REVENUE (Tables)

REVENUE (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Trade Revenue	Net Trade Revenue by Segment and Business or Major Product Line Three Months Ended March 31, In millions 2021 2020 Industrial Solutions $ 458 $ 412 Interconnect Solutions 330 266 Semiconductor Technologies 512 437 Electronics & Industrial $ 1,300 $ 1,115 Safety Solutions $ 637 $ 631 Shelter Solutions 360 348 Water Solutions 331 297 Water & Protection $ 1,328 $ 1,276 Advanced Solutions $ 382 $ 306 Engineering Polymers 497 519 Performance Resins 336 266 Mobility & Materials $ 1,215 $ 1,091 Corporate 1 $ 133 $ 188 Total $ 3,976 $ 3,670 1. Corporate net sales reflect activity of to be divested and previously divested businesses. Net Trade Revenue by Geographic Region Three Months Ended March 31, In millions 2021 2020 U.S. & Canada $ 1,051 $ 1,152 EMEA 1 830 791 Asia Pacific 1,950 1,581 Latin America 145 146 Total $ 3,976 $ 3,670 1. Europe, Middle East and Africa.
Schedule of Contract Balances	Contract Balances March 31, 2021 December 31, 2020 In millions Accounts and notes receivable - trade 1 $ 2,077 $ 1,911 Deferred revenue - current 2 $ 32 $ 16 Deferred revenue - noncurrent 3 $ 20 $ 21 1. Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.

RESTRUCTURING AND ASSET RELAT_2

RESTRUCTURING AND ASSET RELATED CHARGES - NET (Tables)	3 Months Ended
	Mar. 31, 2021
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Charges	The following tables summarize the charges related to the 2020 Restructuring Program: Three Months Ended March 31, In millions 2021 2020 Severance and related benefit costs $ — $ 90 Asset related charges 2 15 Total restructuring and asset related charges - net $ 2 $ 105 2020 Restructuring Program Charges by Segment Three Months Ended March 31, In millions 2021 2020 Electronics & Industrial $ — $ 4 Water & Protection — 20 Mobility & Materials — 24 Corporate 2 57 Total $ 2 $ 105
Schedule of Restructuring Reserve	The following table summarizes the activities related to the 2020 Restructuring Program: 2020 Restructuring Program Severance and Related Benefit Costs Asset Related Charges Total In millions Reserve balance at December 31, 2020 $ 62 $ — $ 62 Year-to-date restructuring charges $ — $ 2 $ 2 Charges against the reserve — (2) (2) Cash payments $ (26) $ — $ (26) Reserve balance at March 31, 2021 $ 36 $ — $ 36

SUPPLEMENTARY INFORMATION (Tabl

SUPPLEMENTARY INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Sundry Income (Expense), Net	Sundry Income (Expense) - Net Three Months Ended March 31, In millions 2021 2020 Non-operating pension and other post-employment benefit (OPEB) credits $ 12 $ 11 Interest income 2 2 Net gain on divestiture and sales of other assets and investments 1 27 197 Foreign exchange losses, net (9) (3) Miscellaneous (expenses) income - net 2 (16) 5 Sundry income (expense) - net $ 16 $ 212 1. The three months ended March 31, 2021 reflects income of $24 million related to the gain on sale of assets within the Electronics & Industrial segment. The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Industrial segment. 2. The three months ended March 31, 2021 includes an impairment charge of approximately $15 million related to Chestnut Run labs, which is part of the Held for Sale Disposal Group.

EARNINGS PER SHARE CALCULATIO_2

EARNINGS PER SHARE CALCULATIONS (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	The following tables provide earnings per share calculations for the three months ended March 31, 2021 and 2020: Net Income for Earnings Per Share Calculations - Basic & Diluted Three Months Ended March 31, In millions 2021 2020 Income (loss) from continuing operations, net of tax $ 541 $ (550) Net income from continuing operations attributable to noncontrolling interests 4 6 Income (loss) from continuing operations attributable to common stockholders $ 537 $ (556) Income (loss) from discontinued operations, net of tax 4,857 (60) Net income from discontinued operations attributable to noncontrolling interests — — Income (loss) from discontinued operations attributable to common stockholders 4,857 (60) Net income (loss) attributable to common stockholders $ 5,394 $ (616) Earnings Per Share Calculations - Basic Three Months Ended March 31, Dollars per share 2021 2020 Earnings (loss) from continuing operations attributable to common stockholders $ 0.89 $ (0.75) Earnings (loss) from discontinued operations, net of tax 8.03 (0.08) Earnings (loss) attributable to common stockholders 2 $ 8.92 $ (0.83) Earnings Per Share Calculations - Diluted Three Months Ended March 31, Dollars per share 2021 2020 Earnings (loss) from continuing operations attributable to common stockholders $ 0.89 $ (0.75) Earnings (loss) from discontinued operations, net of tax 8.01 (0.08) Earnings (loss) attributable to common stockholders 2 $ 8.90 $ (0.83) Share Count Information Three Months Ended March 31, Shares in millions 2021 2020 Weighted-average common shares - basic 604.8 738.6 Plus dilutive effect of equity compensation plans 1.5 — Weighted-average common shares - diluted 606.3 738.6 Stock options and restricted stock units excluded from EPS calculations 1 2.2 6.4 1. These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive. 2. Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

ACCOUNTS AND NOTES RECEIVABLE_2

ACCOUNTS AND NOTES RECEIVABLE - NET (Tables)	3 Months Ended
	Mar. 31, 2021
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable	In millions March 31, 2021 December 31, 2020 Accounts receivable – trade 1 $ 2,015 $ 1,850 Notes receivable – trade 62 61 Other 2 532 510 Total accounts and notes receivable - net $ 2,609 $ 2,421 1. Accounts receivable – trade is net of allowances of $33 million at March 31, 2021 and at December 31, 2020. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts. 2. Other includes receivables in relation to value added tax, fair value of derivative instruments, indemnification assets, and general sales tax and other taxes. No individual group represents more than ten percent of total receivables.

INVENTORIES Inventories (Tables

INVENTORIES Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Current Inventory	Inventories March 31, 2021 December 31, 2020 In millions Finished goods $ 1,526 $ 1,503 Work in process 552 515 Raw materials 294 251 Supplies 127 124 Total inventories $ 2,499 $ 2,393

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Estimated Useful Lives (Years) March 31, 2021 December 31, 2020 In millions Land and land improvements 1 - 25 $ 619 $ 682 Buildings 1 - 50 2,038 2,031 Machinery, equipment, and other 1 - 25 7,211 7,127 Construction in progress 1,235 1,283 Total property, plant and equipment $ 11,103 $ 11,123 Total accumulated depreciation $ 4,359 $ 4,256 Total property, plant and equipment - net $ 6,744 $ 6,867 Three Months Ended March 31, In millions 2021 2020 Depreciation expense $ 161 $ 168

NONCONSOLIDATED AFFILIATES (Tab

NONCONSOLIDATED AFFILIATES (Tables)	3 Months Ended
	Mar. 31, 2021
Equity Method Investments and Joint Ventures [Abstract]
Investments in Nonconsolidated Affiliates	The Company's investments in companies accounted for using the equity method ("nonconsolidated affiliates") are recorded in "Investments and other noncurrent receivables" in the interim Condensed Consolidated Balance Sheets. The Company's net investment in nonconsolidated affiliates is shown in the following table: Investments in Nonconsolidated Affiliates March 31, 2021 December 31, 2020 In millions Investments and other noncurrent receivables $ 902 $ 889 Accrued and other current liabilities (69) (71) Net investment in nonconsolidated affiliates $ 833 $ 818

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amounts of goodwill during the three months ended March 31, 2021 were as follows: Electronics & Industrial Water & Protection Mobility & Materials Total In millions Balance at December 31, 2020 $ 8,458 $ 6,969 $ 3,275 $ 18,702 Currency Translation Adjustment (61) (88) (50) (199) Other — — 8 8 Balance at March 31, 2021 $ 8,397 $ 6,881 $ 3,233 $ 18,511
Schedule of Other Finite Intangible Assets	The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2021 December 31, 2020 In millions Gross Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 2,763 $ (1,181) $ 1,582 $ 2,844 $ (1,220) $ 1,624 Trademarks/tradenames 1,095 (453) 642 1,095 (440) 655 Customer-related 6,979 (2,423) 4,556 7,075 (2,361) 4,714 Other 130 (82) 48 131 (81) 50 Total other intangible assets with finite lives $ 10,967 $ (4,139) $ 6,828 $ 11,145 $ (4,102) $ 7,043 Intangible assets with indefinite lives: Trademarks/tradenames 1,029 — 1,029 1,029 — 1,029 Total other intangible assets 1,029 — 1,029 1,029 — 1,029 Total $ 11,996 $ (4,139) $ 7,857 $ 12,174 $ (4,102) $ 8,072
Schedule of Net Intangibles by Segment	The following table provides the net carrying value of other intangible assets by segment: Net Intangibles by Segment March 31, 2021 December 31, 2020 In millions Electronics & Industrial $ 2,528 $ 2,611 Water & Protection 2,855 2,920 Mobility & Materials 2,474 2,541 Total $ 7,857 $ 8,072
Schedule of Other Indefinite Intangible Assets	The gross carrying amounts and accumulated amortization of other intangible assets by major class are as follows: March 31, 2021 December 31, 2020 In millions Gross Accum Amort Net Gross Carrying Amount Accum Amort Net Intangible assets with finite lives: Developed technology $ 2,763 $ (1,181) $ 1,582 $ 2,844 $ (1,220) $ 1,624 Trademarks/tradenames 1,095 (453) 642 1,095 (440) 655 Customer-related 6,979 (2,423) 4,556 7,075 (2,361) 4,714 Other 130 (82) 48 131 (81) 50 Total other intangible assets with finite lives $ 10,967 $ (4,139) $ 6,828 $ 11,145 $ (4,102) $ 7,043 Intangible assets with indefinite lives: Trademarks/tradenames 1,029 — 1,029 1,029 — 1,029 Total other intangible assets 1,029 — 1,029 1,029 — 1,029 Total $ 11,996 $ (4,139) $ 7,857 $ 12,174 $ (4,102) $ 8,072
Schedule of Estimated Future Amortization Expense	Total estimated amortization expense for the remainder of 2021 and the five succeeding fiscal years is as follows: Estimated Amortization Expense In millions Remainder of 2021 $ 482 2022 $ 628 2023 $ 603 2024 $ 581 2025 $ 535 2026 $ 516

SHORT TERM BORROWINGS, LONG-T_2

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	The following table summarizes the Company's finance lease obligations and long-term debt: Long-Term Debt March 31, 2021 December 31, 2020 In millions Amount Weighted Average Rate Amount Weighted Average Rate Promissory notes and debentures: Final maturity 2021 1 $ 2,000 2.17 % $ — — % Final maturity 2023 2 2,800 3.89 % 4,800 3.18 % Final maturity 2025 2 1,850 4.49 % 1,850 4.49 % Final maturity 2026 and thereafter 2 6,050 5.13 % 6,050 5.13 % Other facilities: Term loan due 2022 — — % 3,000 1.25 % Finance lease obligations 2 2 Less: Unamortized debt discount and issuance costs 80 90 Less: Long-term debt due within one year 1, 3 1,997 1 Total $ 10,625 $ 15,611 1. Represents May 2020 Notes. 2. Represents senior unsecured notes (the "2018 Senior Notes"), which are senior unsecured obligations of the Company.
Schedule of Maturities of Long-term Debt	Principal Payments of long-term debt for the remainder of 2021 and the five succeeding fiscal years are as follows: Maturities of Long-Term Debt for Next Five Years at March 31, 2021 Total In millions Remainder of 2021 $ 2,000 2022 $ — 2023 $ 2,800 2024 $ — 2025 $ 1,850 2026 $ —
Schedule of Line of Credit Facilities	The following table summarizes the Company's credit facilities: Committed and Available Credit Facilities at March 31, 2021 In millions Effective Date Committed Credit Credit Available Maturity Date Interest Revolving Credit Facility, Five May 2019 $ 3,000 $ 2,978 May 2024 Floating Rate 364-day Revolving Credit Facility April 2020 1,000 1,000 April 2021 Floating Rate Total Committed and Available Credit Facilities $ 4,000 $ 3,978

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Guarantor Obligations	The following table provides a summary of the final expiration year and maximum future payments for each type of guarantee: Guarantees at March 31, 2021 Final Expiration Year Maximum Future Payments In millions Obligations for customers 1 : Bank borrowings 2021 $ 15 Obligations for non-consolidated affiliates 2 : Bank borrowings 2021 $ 165 Total guarantees $ 180 1. Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. At March 31, 2021, all maximum future payments had terms less than a year. 2. Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.

OPERATING LEASES Schedule of Le

OPERATING LEASES Schedule of Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Operating Lease Assets and Liabilities	Supplemental balance sheet information related to leases was as follows: In millions March 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets 1 $ 416 $ 423 Current operating lease liabilities 2 98 117 Noncurrent operating lease liabilities 3 320 308 Total operating lease liabilities $ 418 $ 425 1. Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet. 2. Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet. 3. Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.
Schedule of Lease Term and Discount Rates	Lease Term and Discount Rate for Operating Leases March 31, 2021 December 31, 2020 Weighted-average remaining lease term (years) 7.63 6.78 Weighted average discount rate 2.06 % 2.41 %
Schedule of Maturity of Lease Liabilities	Maturities of lease liabilities were as follows: Maturity of Lease Liabilities at March 31, 2021 Operating Leases In millions Remainder of 2021 $ 83 2022 91 2023 70 2024 51 2025 30 2026 and thereafter 133 Total lease payments $ 458 Less: Interest 40 Present value of lease liabilities $ 418

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table summarizes the activity related to each component of accumulated other comprehensive loss ("AOCL") for the three months ended March 31, 2021 and 2020: Accumulated Other Comprehensive Loss Cumulative Translation Adj Pension and OPEB Derivative Instruments Total In millions 2020 Balance at January 1, 2020 $ (1,070) $ (345) $ (1) $ (1,416) Other comprehensive loss before reclassifications (396) (2) — (398) Amounts reclassified from accumulated other comprehensive loss — 4 — 4 Net other comprehensive income (loss) $ (396) $ 2 $ — $ (394) Balance at March 31, 2020 $ (1,466) $ (343) $ (1) $ (1,810) 2021 Balance at January 1, 2021 $ 470 $ (425) $ (1) $ 44 Other comprehensive (loss) income before reclassifications (477) 8 — (469) Amounts reclassified from accumulated other comprehensive loss — 4 — 4 Split-off of N&B reclassification adjustment 184 73 1 258 Net other comprehensive (loss) income $ (293) $ 85 $ 1 $ (207) Balance at March 31, 2021 $ 177 $ (340) $ — $ (163)
Schedule of Reclassifications Out of Accumulated Other Comprehensive Income	A summary of the reclassifications out of AOCL for the three months ended March 31, 2021 and 2020 is provided as follows: Reclassifications Out of Accumulated Other Comprehensive Loss Three Months Ended Income Classification In millions 2021 2020 Cumulative translation adjustments $ 184 $ — See (1) below Pension and other post-employment benefit plans $ 106 $ 3 See (1) below Tax (benefit) expense (29) 1 See (1) below After tax $ 77 $ 4 Derivative Instruments $ 1 $ — See (1) below Total reclassifications for the period, after tax $ 262 $ 4 1. The activity for the three months ended March 31, 2021 is classified within "Income (loss) from discontinued operations, net of tax" and "Sundry income (expense) - net" as part of the N&B Transaction and continuing operations, respectively. The activity for the three months ended March 31, 2020 is classified within the "Sundry income (expense) - net" and "Provision for income taxes on continuing operations" lines.

NONCONTROLLING INTERESTS (Table

NONCONTROLLING INTERESTS (Tables)	3 Months Ended
	Mar. 31, 2021
Noncontrolling Interest [Abstract]
Schedule Of Noncontrolling Interest	The following table summarizes the activity for equity attributable to noncontrolling interests for the three months ended March 31, 2021 and 2020: Noncontrolling Interests Three Months Ended March 31, In millions 2021 2020 Balance at beginning of period $ 566 $ 569 Net income attributable to noncontrolling interests 4 6 Distributions to noncontrolling interests (19) (6) Cumulative translation adjustments (7) (8) Split-off of N&B (27) — Other — 5 Balance at end of period $ 517 $ 566

PENSION PLANS AND OTHER POST-_2

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS (Tables)	3 Months Ended
	Mar. 31, 2021
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following sets forth the components of the Company's net periodic benefit (credit) cost for defined benefit pension plans: Net Periodic Benefit (Credit) Cost for All Plans Three Months Ended March 31, In millions 2021 2020 Defined Benefit Pension Plans: Service cost 1 $ 15 $ 18 Interest cost 2 11 14 Expected return on plan assets 3 (28) (28) Amortization of prior service credit 4 (1) (1) Amortization of net loss 5 3 4 Curtailment/settlement 6 2 — Net periodic benefit cost - total $ 2 $ 7 Less: Net periodic benefit cost - discontinued operations 1 4 Net periodic benefit cost - continuing operations $ 1 $ 3 1. The service cost from continuing operations was $13 million and $14 million for the three months ended March 31, 2021 and 2020, respectively. 2. The interest cost from continuing operations was $11 million and $13 million for the three months ended March 31, 2021 and 2020, respectively. 3. The expected return on plan assets from continuing operations was $27 million and $26 million for the three months ended March 31, 2021 and 2020, respectively. 4. The amortization of prior service credit from continuing operations a gain of $1 million for both the three months ended March 31, 2021 and 2020. 5. The amortization of unrecognized net loss from continuing operations was $3 million for both the three months ended March 31, 2021 and 2020. 6. The curtailment and settlement costs from continuing operations was $2 million for the three months ended March 31, 2021. There were no curtailment or settlement costs from continuing operations for the three months ended March 31, 2020.

FINANCIAL INSTRUMENTS (Tables)

FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2021
Investments, All Other Investments [Abstract]
Schedule of the Fair Value of Financial Instruments	The following table summarizes the fair value of financial instruments at March 31, 2021 and December 31, 2020: Fair Value of Financial Instruments March 31, 2021 December 31, 2020 In millions Cost Gain Loss Fair Value Cost Gain Loss Fair Value Cash equivalents $ 3,246 $ — $ — $ 3,246 $ 1,105 $ — $ — $ 1,105 Restricted cash equivalents 1 $ 14 $ — $ — $ 14 $ 6,223 $ — $ — $ 6,223 Marketable securities $ 2,001 $ — $ — $ 2,001 $ — $ — $ — $ — Total cash equivalents, restricted cash equivalents and marketable securities $ 5,261 $ — $ — $ 5,261 $ 7,328 $ — $ — $ 7,328 Long-term debt including debt due within one year $ (12,622) $ — $ (2,002) $ (14,624) $ (15,612) $ — $ (2,725) $ (18,337) Derivatives relating to: Foreign currency 2 — 13 (10) 3 — 4 (13) (9) Total derivatives $ — $ 13 $ (10) $ 3 $ — $ 4 $ (13) $ (9) 1. Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets. 2. Presented net of cash collateral where master netting arrangements allow.
Schedule of Notional Amounts	The notional amounts of the Company's derivative instruments were as follows: Notional Amounts March 31, 2021 Dec 31, 2020 In millions Derivatives not designated as hedging instruments: Foreign currency contracts 1 $ 84 $ (304) 1. Presented net of contracts bought and sold.

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of the Fair Value of Assets and Liabilities Measured on a Recurring Basis	The following tables summarize the basis used to measure certain assets and liabilities at fair value on a recurring basis: Basis of Fair Value Measurements on a Recurring Basis at March 31, 2021 Significant Other Observable Inputs In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 3,260 Marketable securities 2 2,001 Derivatives relating to: 3 Foreign currency contracts 4 20 Total assets at fair value $ 5,281 Liabilities at fair value: Long-term debt including debt due within one year 5 $ 14,624 Derivatives relating to: 3 Foreign currency contracts 4 17 Total liabilities at fair value $ 14,641 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. Primarily time deposits with maturities of greater than three months at time of acquisition. 3. See Note 20 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 4. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $7 million for both assets and liabilities as of March 31, 2021. 5. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms. Basis of Fair Value Measurements on a Recurring Basis at December 31, 2020 Significant Other Observable Inputs In millions Assets at fair value: Cash equivalents and restricted cash equivalents 1 $ 7,328 Derivatives relating to: 2 Foreign currency contracts 3 13 Total assets at fair value $ 7,341 Liabilities at fair value: Long-term debt including debt due within one year 4 $ 18,337 Derivatives relating to: 2 Foreign currency contracts 3 22 Total liabilities at fair value $ 18,359 1. Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value. 2. See Note 20 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets. 3. Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $9 million for both assets and liabilities as of December 31, 2020. 4. Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.

SEGMENTS AND GEOGRAPHIC REGIO_2

SEGMENTS AND GEOGRAPHIC REGIONS (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Operating Segment Information	Segment Information Elect. & Industrial Water & Protection Mobility & Materials Corporate 1 Total In millions Three Months Ended March 31, 2021 Net sales $ 1,300 $ 1,328 $ 1,215 $ 133 $ 3,976 Operating EBITDA 2 $ 436 $ 355 $ 278 $ (22) $ 1,047 Equity in earnings of nonconsolidated affiliates $ 9 $ 12 $ 3 $ 2 $ 26 Three months ended March 31, 2020 Net sales $ 1,115 $ 1,276 $ 1,091 $ 188 $ 3,670 Operating EBITDA 2 $ 327 $ 357 $ 215 $ 8 $ 907 Equity in earnings of nonconsolidated affiliates $ 9 $ 7 $ 1 $ 22 $ 39 1. Corporate includes activity of to be divested and previously divested businesses. 2. A reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA is provided below.
Schedule of Reconciliation of Income (Loss) from Continuing Operations	Reconciliation of "Income (loss) from continuing operations, net of tax" to Operating EBITDA for the Three Months Ended March 31, 2021 and 2020 Three Months Ended March 31, In millions 2021 2020 Income (Loss) from continuing operations, net of tax $ 541 $ (550) + Provision for income taxes on continuing operations 32 94 Income (Loss) from continuing operations before income taxes $ 573 $ (456) + Depreciation and amortization 328 345 - Interest income 1 2 2 + Interest expense 146 171 - Non-operating pension/OPEB benefit 1 12 11 - Foreign exchange losses, net 1 (9) (3) - Significant items (5) (857) Operating EBITDA $ 1,047 $ 907 1. Included in "Sundry income (expense) - net."
Schedule of Certain Items by Segment	The following tables summarize the pre-tax impact of significant items by segment that are excluded from Operating EBITDA above: Significant Items by Segment for the Three Months Ended March 31, 2021 Elect. & Industrial Water & Protection Mobility & Materials Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ (6) $ (6) Restructuring and asset related charges - net 2 — — — (2) (2) Gain on divestiture 3 2 — — 1 3 Total $ 2 $ — $ — $ (7) $ (5) 1. Integration and separation costs related to strategic initiatives including the divestiture of the Held for Sale Disposal Group. 2. Includes Board approved restructuring plans and asset related charges. See Note 4 for additional information. 3. Reflected in "Sundry income (expense) - net." Significant Items by Segment for the Three Months Ended March 31, 2020 Elect. & Industrial Water & Protection Mobility & Materials Corporate Total In millions Integration and separation costs 1 $ — $ — $ — $ (123) $ (123) Restructuring and asset related charges - net 2 (4) (25) (25) (74) (128) Goodwill impairment charge 3 — — — (533) (533) Asset impairment charges 4 — — — (270) (270) Gain on divestiture 5 197 — — — 197 Total $ 193 $ (25) $ (25) $ (1,000) $ (857) 1. Integration and separation costs related to the post-DWDP Merger integration and the DWDP Distributions. 2. Includes Board approved restructuring plans and asset related charges. See Note 4 for additional information. 3. See Note 12 for additional information. 4. See Note 4 for additional information. 5. Reflected in "Sundry income (expense) - net." See Note 2 for additional information.

ACQUISITIONS AND DIVESTITURES N

ACQUISITIONS AND DIVESTITURES Narrative (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Feb. 01, 2021	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)		$ 0.01				$ 0.01
Restricted cash		$ 0				$ 6,206
Long-term debt including debt due within one year, Cost		12,622				$ 15,612
DuPont
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.01
N&B Notes Offering | Unsecured Debt
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Face amount of debt	$ 6,250
Nutrition & Biosciences Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses	$ 7,300
Nutrition & Biosciences Business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares accepted and retired in exchange offer	197.4
Shares exchanged in exchange offer	141.7
Non-taxable gain on split-off		$ 4,954	$ 0
Nutrition & Biosciences Business | Nutrition & Biosciences Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.01
Nutrition & Biosciences Business | International Flavors & Fragrances Inc. | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Par value (in usd per share)	$ 0.125
Nutrition & Biosciences Business | N&B Term Loan Facility
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Face amount of debt	$ 1,250
Nutrition & Biosciences Business | N&B Senior Unsecured Notes
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Long-term debt including debt due within one year, Cost	$ 6,200
Compound Semiconductor Solutions Business Unit | Disposal Group, Disposed of by Sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses			$ 420
Forecast | Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration for sale of business unit					$ 920
Laird Performance Materials | Forecast
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business combination, consideration transferred				$ 2,300

ACQUISITIONS AND DIVESTITURES D

ACQUISITIONS AND DIVESTITURES Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations, net of tax	$ 4,857	$ (60)
Nutrition & Biosciences Business | Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net sales	507	1,551
Cost of sales	352	999
Research and development expenses	21	63
Selling, general and administrative expenses	44	151
Amortization of intangibles	38	355
Restructuring and asset related charges - net	1	6
Integration and separation costs	149	74
Sundry income (expense) - net	(2)	(1)
Interest expense	13	12
Loss from discontinued operations before income taxes	(113)	(110)
Benefit from income taxes on discontinued operations	(21)	(50)
Income (loss) from discontinued operations, net of tax	(92)	(60)
Non-taxable gain on split-off	4,954	0
Income (loss) from discontinued operations attributable to DuPont stockholders, net of tax	$ 4,862	$ (60)

ACQUISITIONS AND DIVESTITURES_2

ACQUISITIONS AND DIVESTITURES Depreciation, Amortization and Capital Expenditures (Details) - Nutrition & Biosciences Business - Discontinued Operations - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation and amortization	$ 63	$ 427
Capital expenditures	$ 27	$ 92

ACQUISITIONS AND DIVESTITURES C

ACQUISITIONS AND DIVESTITURES Carrying Amount of Assets and Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Disposal Group, Held-for-sale, Not Discontinued Operations
Assets
Accounts and notes receivable - net	$ 68	$ 63
Inventories	72	75
Other current assets	36	35
Investments and noncurrent receivables	166	164
Property, plant, and equipment - net	83	34
Goodwill	267	267
Other intangible assets - net	168	168
Deferred charges and other assets	3	4
Total assets of discontinued operations	863	810
Liabilities
Accounts payable	44	40
Income taxes payable	3	1
Accrued and other current liabilities	40	50
Deferred income tax liabilities	29	30
Pension and other post employment benefits - noncurrent	1	1
Other noncurrent obligations	16	18
Total liabilities of discontinued operations	$ 133	140
Discontinued Operations | Nutrition & Biosciences Business
Assets
Accounts and notes receivable - net		1,130
Inventories		1,333
Other current assets		65
Investments and noncurrent receivables		36
Property, plant, and equipment - net		3,118
Goodwill		11,542
Other intangible assets - net		3,072
Deferred income tax assets		44
Deferred charges and other assets		319
Total assets of discontinued operations		20,659
Liabilities
Short-term borrowings and finance lease obligations		4
Accounts payable		742
Income taxes payable		36
Accrued and other current liabilities		301
Long-term debt		6,195
Deferred income tax liabilities		852
Pension and other post employment benefits - noncurrent		238
Other noncurrent obligations		242
Total liabilities of discontinued operations		$ 8,610

ACQUISITIONS AND DIVESTITURES O

ACQUISITIONS AND DIVESTITURES Other Divestitures (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Pre-tax gain	$ 3	$ 197
Integration and separation costs	$ 6	123
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Compound Semiconductor Solutions Business Unit
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from divestiture of businesses		420
Pre-tax gain		197
Gain net of tax		$ 102

REVENUE (Details)

REVENUE (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue, Major Customer [Line Items]
Net sales		$ 3,976	$ 3,670
Accounts and notes receivable - trade	[1]	2,077		$ 1,911
Deferred revenue - current	[2]	32		16
Deferred revenue - noncurrent	[3]	20		$ 21
U.S. & Canada
Revenue, Major Customer [Line Items]
Net sales		1,051	1,152
EMEA
Revenue, Major Customer [Line Items]
Net sales	[4]	830	791
Asia Pacific
Revenue, Major Customer [Line Items]
Net sales		1,950	1,581
Latin America
Revenue, Major Customer [Line Items]
Net sales		145	146
Electronics & Industrial
Revenue, Major Customer [Line Items]
Net sales		1,300	1,115
Electronics & Industrial | Industrial Solutions
Revenue, Major Customer [Line Items]
Net sales		458	412
Electronics & Industrial | Interconnect Solutions
Revenue, Major Customer [Line Items]
Net sales		330	266
Electronics & Industrial | Semiconductor Technologies
Revenue, Major Customer [Line Items]
Net sales		512	437
Water & Protection
Revenue, Major Customer [Line Items]
Net sales		1,328	1,276
Water & Protection | Safety Solutions
Revenue, Major Customer [Line Items]
Net sales		637	631
Water & Protection | Shelter Solutions
Revenue, Major Customer [Line Items]
Net sales		360	348
Water & Protection | Water Solutions
Revenue, Major Customer [Line Items]
Net sales		331	297
Mobility & Materials
Revenue, Major Customer [Line Items]
Net sales		1,215	1,091
Mobility & Materials | Advanced Solutions
Revenue, Major Customer [Line Items]
Net sales		382	306
Mobility & Materials | Engineering Polymers
Revenue, Major Customer [Line Items]
Net sales		497	519
Mobility & Materials | Performance Resins
Revenue, Major Customer [Line Items]
Net sales		336	266
Corporate
Revenue, Major Customer [Line Items]
Net sales		$ 133	$ 188
[1]	Included in "Accounts and notes receivable - net" in the interim Condensed Consolidated Balance Sheets.
[2]	Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheets.
[3]	Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheets.
[4]	Europe, Middle East and Africa.

RESTRUCTURING AND ASSET RELAT_3

RESTRUCTURING AND ASSET RELATED CHARGES - NET Narrative (Details) - USD ($) $ in Millions	Apr. 15, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring reserve		$ 55		$ 96
Pre-tax impairment charge			$ 270
Revolving Credit Facility, Five-year
Restructuring Cost and Reserve [Line Items]
Term		5 years
Revolving Credit Facility, Five-year | 364-day Revolving Credit Facility
Restructuring Cost and Reserve [Line Items]
Term		364 days
Revolving Credit Facility, Five-year | 364-day Revolving Credit Facility | Subsequent Event
Restructuring Cost and Reserve [Line Items]
Term	364 days
Biomaterials Business Unit
Restructuring Cost and Reserve [Line Items]
Pre-tax impairment charge			$ 270

RESTRUCTURING AND ASSET RELAT_4

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2020 Restructuring Program (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 2	$ 398
Restructuring Reserve [Roll Forward]
Reserve balance at December 31, 2020	96
Year-to-date restructuring charges	2	398
Reserve balance at March 31, 2021	55
2020 Restructuring Program
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	170
Restructuring charges	2	105
Restructuring Reserve [Roll Forward]
Reserve balance at December 31, 2020	62
Year-to-date restructuring charges	2	105
Charges against the reserve	(2)
Cash payments	(26)
Reserve balance at March 31, 2021	36
Liabilities recorded in "Accrued and other current liabilities"	36	62
2020 Restructuring Program | Electronics & Industrial
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	4
Restructuring Reserve [Roll Forward]
Year-to-date restructuring charges	0	4
2020 Restructuring Program | Water & Protection
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	20
Restructuring Reserve [Roll Forward]
Year-to-date restructuring charges	0	20
2020 Restructuring Program | Mobility & Materials
Restructuring Cost and Reserve [Line Items]
Restructuring charges	0	24
Restructuring Reserve [Roll Forward]
Year-to-date restructuring charges	0	24
2020 Restructuring Program | Corporate
Restructuring Cost and Reserve [Line Items]
Restructuring charges	2	57
Restructuring Reserve [Roll Forward]
Year-to-date restructuring charges	2	57
2020 Restructuring Program | Severance and Related Benefit Costs
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	118
Restructuring charges	0	90
Restructuring Reserve [Roll Forward]
Reserve balance at December 31, 2020	62
Year-to-date restructuring charges	0	90
Charges against the reserve	0
Cash payments	(26)
Reserve balance at March 31, 2021	36
2020 Restructuring Program | Asset Related Charges
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	52
Restructuring charges	2	15
Restructuring Reserve [Roll Forward]
Reserve balance at December 31, 2020	0
Year-to-date restructuring charges	2	$ 15
Charges against the reserve	(2)
Cash payments	0
Reserve balance at March 31, 2021	$ 0

RESTRUCTURING AND ASSET RELAT_5

RESTRUCTURING AND ASSET RELATED CHARGES - NET 2019 Restructuring Program (Details) - 2019 Restructuring Program - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	$ 124
Liabilities recorded in "Accrued and other current liabilities"	6	$ 14
Severance and Related Benefit Costs
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	97
Asset Related Charges
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	$ 27

RESTRUCTURING AND ASSET RELAT_6

RESTRUCTURING AND ASSET RELATED CHARGES - NET DowDuPont Cost Synergy Program (Details) - DowDuPont Cost Synergy Program - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	$ 346
Liabilities recorded in "Accrued and other current liabilities"	13	$ 20
Severance and Related Benefit Costs
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	138
Asset Related Charges
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	159
Contract Termination
Restructuring Cost and Reserve [Line Items]
Pre-tax restructuring charges from inception-to-date	$ 49

SUPPLEMENTARY INFORMATION - Sum

SUPPLEMENTARY INFORMATION - Summary of Sundry Income (Expense) - Net (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021		Mar. 31, 2020
Schedule Of Sundry Income (Expense) [Line Items]
Non-operating pension and other post-employment benefit (OPEB) credits		$ 12		$ 11
Interest income		2		2
Net gain on divestiture and sales of other assets and investments	[1]	27		197
Foreign exchange losses, net		(9)		(3)
Miscellaneous (expenses) income - net		(16)	[2]	5
Sundry income (expense) - net		16		212
Pre-tax impairment charge				270
Disposal Group, Held-for-sale, Not Discontinued Operations | Chestnut Run
Schedule Of Sundry Income (Expense) [Line Items]
Pre-tax impairment charge		15
Electronics & Imaging
Schedule Of Sundry Income (Expense) [Line Items]
Net gain on divestiture and sales of other assets and investments		$ 24		197
Pre-tax impairment charge				$ 0
[1]	The three months ended March 31, 2021 reflects income of $24 million related to the gain on sale of assets within the Electronics & Industrial segment. The three months ended March 31, 2020 reflects income of $197 million related to the gain on sale of the Compound Semiconductor Solutions business unit within the Electronics & Industrial segment.
[2]	The three months ended March 31, 2021 includes an impairment charge of approximately $15 million related to Chestnut Run labs, which is part of the Held for Sale Disposal Group.

SUPPLEMENTARY INFORMATION - Cas

SUPPLEMENTARY INFORMATION - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2021	Feb. 01, 2021	Dec. 31, 2020
Supplementary Information
Restricted cash	$ 0		$ 6,206
Net proceeds from offering	$ 4,000
N&B Bridge Loan
Supplementary Information
Net proceeds from offering		$ 6,250

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Disclosure [Abstract]
Effective tax rate, percent	5.60%	(20.60%)
Tax benefit related to step-up in tax basis in goodwill	$ 59

EARNINGS PER SHARE CALCULATIO_3

EARNINGS PER SHARE CALCULATIONS - Summary of Net Income for EPS Calculations, Basic (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Income (loss) from continuing operations, net of tax	$ 541	$ (550)
Net income from continuing operations attributable to noncontrolling interests	4	6
Income (loss) from continuing operations attributable to common stockholders	537	(556)
Income (loss) from discontinued operations, net of tax	4,857	(60)
Net income from discontinued operations attributable to noncontrolling interests	0	0
Income (loss) from discontinued operations attributable to common stockholders	4,857	(60)
Net income (loss) attributable to common stockholders	$ 5,394	$ (616)

EARNINGS PER SHARE CALCULATIO_4

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Basic (Details) - $ / shares		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings (loss) from continuing operations attributable to common stockholders		$ 0.89	$ (0.75)
Earnings (loss) from discontinued operations, net of tax		8.03	(0.08)
Earnings (loss) per common share - basic (in usd per share)	[1]	$ 8.92	$ (0.83)
[1]	Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

EARNINGS PER SHARE CALCULATIO_5

EARNINGS PER SHARE CALCULATIONS - Summary of EPS Calculations, Diluted (Details) - $ / shares		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Earnings (loss) from continuing operations attributable to common stockholders		$ 0.89	$ (0.75)
Earnings (loss) from discontinued operations, net of tax		8.01	(0.08)
Earnings (loss) per common share - diluted (in usd per share)	[1]	$ 8.90	$ (0.83)
[1]	Earnings per share amounts are computed independently for income from continuing operations, income from discontinued operations and net income attributable to common stockholders. As a result, the per share amounts from continuing operations and discontinued operations may not equal the total per share amounts for net income attributable to common stockholders.

EARNINGS PER SHARE CALCULATIO_6

EARNINGS PER SHARE CALCULATIONS - Summary of Count Information (Details) - shares shares in Millions		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Weighted-average common shares - basic		604.8	738.6
Plus dilutive effect of equity compensation plans		1.5	0
Weighted-average common shares - diluted		606.3	738.6
Stock options and restricted stock units excluded from EPS calculations	[1]	2.2	6.4
[1]	These outstanding options to purchase shares of common stock and restricted stock units were excluded from the calculation of diluted earnings per share because the effect of including them would have been antidilutive.

ACCOUNTS AND NOTES RECEIVABLE_3

ACCOUNTS AND NOTES RECEIVABLE - NET (Details) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Receivables [Abstract]
Accounts Receivable - trade	[1]	$ 2,015	$ 1,850
Notes receivable – trade		62	61
Other	[2]	532	510
Total accounts and notes receivable - net		2,609	2,421
Accounts and notes receivables - trade, allowance		$ 33	$ 33
[1]	Accounts receivable – trade is net of allowances of $33 million at March 31, 2021 and      at December 31, 2020. Allowances are equal to the estimated uncollectible amounts and current expected credit loss. That estimate is based on historical collection experience, current economic and market conditions, and review of the current status of customers' accounts.
[2]	Other includes receivables in relation to value added tax, fair value of derivative instruments, indemnification assets, and general sales tax and other taxes. No individual group represents more than ten percent of total receivables.

INVENTORIES (Summary of Invento

INVENTORIES (Summary of Inventory) (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Finished goods	$ 1,526	$ 1,503
Work in process	552	515
Raw materials	294	251
Supplies	127	124
Total inventories	$ 2,499	$ 2,393

PROPERTY, PLANT AND EQUIPMENT S

PROPERTY, PLANT AND EQUIPMENT Schedule of Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 11,103	$ 11,123
Total accumulated depreciation	4,359	4,256
Total property, plant and equipment - net	6,744	6,867
Land and land improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	619	682
Buildings
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	2,038	2,031
Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	7,211	7,127
Construction in progress
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 1,235	$ 1,283
Minimum | Land and land improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Minimum | Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Minimum | Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	1 year
Maximum | Land and land improvements
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	25 years
Maximum | Buildings
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	50 years
Maximum | Machinery, equipment, and other
Property, Plant and Equipment [Line Items]
Estimated Useful Lives (Years)	25 years

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT Schedule of Depreciation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation	$ 161	$ 168

NONCONSOLIDATED AFFILIATES NONC

NONCONSOLIDATED AFFILIATES NONCONSOLIDATED AFFILIATES (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)entity	Mar. 31, 2020	Dec. 31, 2020USD ($)
Investments in and Advances to Affiliates [Line Items]
Investments and other noncurrent receivables	$ 902		$ 889
Accrued and other current liabilities	(69)		(71)
Net investment in nonconsolidated affiliates	$ 833		$ 818
Ownership interest affiliates | entity	14
Equity Method Investee | Customer Concentration Risk | Revenue Benchmark
Investments in and Advances to Affiliates [Line Items]
Concentration risk, percentage	2.00%	3.00%
Equity Method Investee | Supplier Concentration Risk | Cost of Goods and Service Benchmark
Investments in and Advances to Affiliates [Line Items]
Concentration risk, percentage	4.00%	4.00%

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Goodwill (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Goodwill [Roll Forward]
Net goodwill, beginning of period	$ 18,702
Currency Translation Adjustment	(199)
Other	8
Net goodwill, end of period	18,511
Electronics & Industrial
Goodwill [Roll Forward]
Net goodwill, beginning of period	8,458
Currency Translation Adjustment	(61)
Other	0
Net goodwill, end of period	8,397
Water & Protection
Goodwill [Roll Forward]
Net goodwill, beginning of period	6,969
Currency Translation Adjustment	(88)
Other	0
Net goodwill, end of period	6,881
Mobility & Materials
Goodwill [Roll Forward]
Net goodwill, beginning of period	3,275
Currency Translation Adjustment	(50)
Other	8
Net goodwill, end of period	$ 3,233

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment charge	$ 0	$ 533

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Other Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 10,967	$ 11,145
Accum Amort	(4,139)	(4,102)
Net	6,828	7,043
Indefinite-lived Intangible Assets [Line Items]
Total other intangible assets	1,029	1,029
Gross Carrying Amount	11,996	12,174
Net	7,857	8,072
Trademarks/tradenames
Indefinite-lived Intangible Assets [Line Items]
Total other intangible assets	1,029	1,029
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,763	2,844
Accum Amort	(1,181)	(1,220)
Net	1,582	1,624
Trademarks/tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,095	1,095
Accum Amort	(453)	(440)
Net	642	655
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,979	7,075
Accum Amort	(2,423)	(2,361)
Net	4,556	4,714
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	130	131
Accum Amort	(82)	(81)
Net	$ 48	$ 50

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS - Summary of Intangibles by Segment (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 7,857	$ 8,072
Electronics & Industrial
Schedule of Intangible Assets [Line Items]
Other intangible assets	2,528	2,611
Water & Protection
Schedule of Intangible Assets [Line Items]
Other intangible assets	2,855	2,920
Mobility & Materials
Schedule of Intangible Assets [Line Items]
Other intangible assets	$ 2,474	$ 2,541

GOODWILL AND OTHER INTANGIBLE_7

GOODWILL AND OTHER INTANGIBLE ASSETS - Amortization (Details) $ in Millions	Mar. 31, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 482
2022	628
2023	603
2024	581
2025	535
2026	$ 516

SHORT TERM BORROWINGS, LONG-T_3

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term debt, current	$ 1,997	$ 1
Level 2 | Recurring
Debt Instrument [Line Items]
Long-term debt	$ 12,617	$ 18,336

SHORT TERM BORROWINGS, LONG-T_4

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Long-Term Debt (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Finance lease obligations	$ 2	$ 2
Less: Unamortized debt discount and issuance costs	80	90
Less: Long-term debt due within one year	1,997	1
Long-Term Debt	$ 10,625	$ 15,611
Term loan due 2022
Debt Instrument [Line Items]
Weighted Average Rate	0.00%	1.25%
Promissory Notes And Debentures, Final Maturity, 2021 | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,000	$ 0
Weighted Average Rate	2.17%	0.00%
Promissory Notes And Debentures, Final Maturity, 2023 | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,800	$ 4,800
Weighted Average Rate	3.89%	3.18%
Promissory Notes And Debentures, Final Maturity, 2025 | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,850	$ 1,850
Weighted Average Rate	4.49%	4.49%
Promissory Notes And Debentures, Final Maturity, 2026 and thereafter | Loans Payable
Debt Instrument [Line Items]
Long-term debt, gross	$ 6,050	$ 6,050
Weighted Average Rate	5.13%	5.13%
Term loan due 2022
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 3,000

SHORT TERM BORROWINGS, LONG-T_5

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Maturities of Long-Term Debt for Next Five Years (Details) $ in Millions	Mar. 31, 2021USD ($)
Debt Disclosure [Abstract]
Remainder of 2021	$ 2,000,000
2022	0
2023	2,800,000
2024	0
2025	1,850,000
2026	$ 0

SHORT TERM BORROWINGS, LONG-T_6

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Committed and Available Credit Facilities (Details) - USD ($)	Apr. 15, 2021	Mar. 31, 2021
Line of Credit Facility [Line Items]
Committed Credit		$ 4,000,000,000
Credit Available		$ 3,978,000,000
Revolving Credit Facility, Five-year
Line of Credit Facility [Line Items]
Term		5 years
Revolving Credit Facility, Five-year
Line of Credit Facility [Line Items]
Committed Credit		$ 3,000,000,000
Credit Available		2,978,000,000
364-day Revolving Credit Facility
Line of Credit Facility [Line Items]
Committed Credit		1,000,000,000
Credit Available		$ 1,000,000,000
364-day Revolving Credit Facility | Revolving Credit Facility, Five-year
Line of Credit Facility [Line Items]
Term		364 days
364-day Revolving Credit Facility | Subsequent Event | Revolving Credit Facility, Five-year
Line of Credit Facility [Line Items]
Current revolving credit facility	$ 1,000,000,000
Term	364 days

SHORT TERM BORROWINGS, LONG-T_7

SHORT TERM BORROWINGS, LONG-TERM DEBT AND AVAILABLE CREDIT FACILITIES Additional Information (Details)	Feb. 01, 2021USD ($)	Mar. 31, 2021USD ($)
Line of Credit Facility [Line Items]
Remaining borrowing capacity, uncommitted		$ 749,000,000
Letters of credit outstanding		$ 138,000,000
Ratio of indebtedness to net capital		0.60
Nutrition & Biosciences Business
Line of Credit Facility [Line Items]
Proceeds from divestiture of businesses	$ 7,300,000,000
N&B Term Loan Facility | Nutrition & Biosciences Business
Line of Credit Facility [Line Items]
Face amount of debt	1,250,000,000
Term loan due 2022
Line of Credit Facility [Line Items]
Face amount of debt	$ 3,000,000,000

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES - Narrative (Details) $ in Thousands	1 Months Ended		2 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2021USD ($)case	Mar. 31, 2020USD ($)case	Mar. 31, 2021USD ($)case	Mar. 31, 2021USD ($)case	Dec. 31, 2017USD ($)
Loss Contingencies [Line Items]
Estimated litigation liability	$ 18,000		$ 18,000	$ 18,000
Non-PFAS stray liabilities threshold	200,000		200,000	200,000
Indemnifiable losses threshold related to PFAS stray liabilities - total	300,000		300,000	300,000
Indemnifiable losses threshold related to PFAS stray liabilities - per party	150,000		150,000	150,000
Qualified spend - eligible PFAS costs, maximum	4,000,000		4,000,000	4,000,000
Escrow account balance - required minimum	700,000		700,000	700,000
Eligible PFAS Costs
Loss Contingencies [Line Items]
Indemnification liabilities	62,000		62,000	62,000
Accounts And Notes Receivable, Other
Loss Contingencies [Line Items]
Indemnification asset	80,000		80,000	80,000
Deferred Charges And Other Assets
Loss Contingencies [Line Items]
Indemnification asset	228,000		228,000	228,000
Accrued and Other Current Liabilities
Loss Contingencies [Line Items]
Indemnification liabilities	160,000		160,000	160,000
Other noncurrent obligations
Loss Contingencies [Line Items]
Indemnification liabilities	$ 140,000		$ 140,000	140,000
PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of lawsuits | case		100
PFOA Multi-District Litigation (MDL) | PFOA Matters
Loss Contingencies [Line Items]
Amount awarded to other party				$ 83,000
DuPont and Corteva
Loss Contingencies [Line Items]
Percentage split of PFAS liabilities under the separation agreement	50.00%		50.00%	50.00%
DuPont
Loss Contingencies [Line Items]
Non-PFAS stray liabilities percent split after threshold	71.00%		71.00%	71.00%
DuPont | PFOA Multi-District Litigation (MDL) | PFOA Matters
Loss Contingencies [Line Items]
Liabilities remaining	$ 11,000		$ 11,000	$ 11,000
Amount awarded to other party				$ 27,000
Payments			$ 16,000
Corteva
Loss Contingencies [Line Items]
Non-PFAS stray liabilities percent split after threshold	29.00%		29.00%	29.00%
DuPont and Corteva
Loss Contingencies [Line Items]
Qualified spend - eligible PFAS costs, maximum	$ 2,000,000		$ 2,000,000	$ 2,000,000
Qualified spend - eligible PFAS costs percentage split	50.00%		50.00%	50.00%
Future escrow deposit, percentage split	50.00%		50.00%	50.00%
DuPont and Corteva | Payments due September 2021, September 2022
Loss Contingencies [Line Items]
Future escrow deposit	$ 100,000		$ 100,000	$ 100,000
DuPont and Corteva | Payments due annually beginning September 2023
Loss Contingencies [Line Items]
Future escrow deposit	$ 50,000		$ 50,000	$ 50,000
Chemours
Loss Contingencies [Line Items]
Qualified spend - eligible PFAS costs percentage split	50.00%		50.00%	50.00%
Future escrow deposit, percentage split	50.00%		50.00%	50.00%
Chemours | Payments due September 2021, September 2022
Loss Contingencies [Line Items]
Future escrow deposit	$ 100,000		$ 100,000	$ 100,000
Chemours | Payments due annually beginning September 2023
Loss Contingencies [Line Items]
Future escrow deposit	$ 50,000		$ 50,000	50,000
Chemours | PFOA Multi-District Litigation (MDL) | PFOA Matters
Loss Contingencies [Line Items]
Amount awarded to other party				$ 29,000
Historical EID And Chemours | PFOA Multi-District Litigation (MDL) | PFOA Matters
Loss Contingencies [Line Items]
Amount awarded to other party					$ 335,000
Historical EID And Chemours | Firefighter Foam Cases
Loss Contingencies [Line Items]
Number of lawsuits | case	1,020		1,020	1,020
EID | Abbott Case
Loss Contingencies [Line Items]
Amount awarded to other party		$ 50,000
EID | Abbott Case | Judicial Ruling
Loss Contingencies [Line Items]
Amount awarded to other party	$ 40,250
Loss of consortium	$ 250	$ 10,000	$ 250	$ 250

COMMITMENTS AND CONTINGENT LI_4

COMMITMENTS AND CONTINGENT LIABILITIES - PFOA & Natural Resources (Details) $ in Thousands	1 Months Ended		3 Months Ended			12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)case	Mar. 31, 2021USD ($)plaintiff	Sep. 30, 2020case	Mar. 31, 2017plaintiff	Dec. 31, 2017USD ($)
PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Number of lawsuits | case		100
Abbott Case | EID
Loss Contingencies [Line Items]
Amount awarded to other party		$ 50,000
Abbott Case | EID | Judicial Ruling
Loss Contingencies [Line Items]
Amount awarded to other party	$ 40,250
PFOA Matters | PFOA Multi-District Litigation (MDL)
Loss Contingencies [Line Items]
Amount awarded to other party			$ 83,000
PFOA Matters | PFOA Multi-District Litigation (MDL) | DuPont
Loss Contingencies [Line Items]
Amount awarded to other party			27,000
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff					3,550
PFOA Matters | PFOA Multi-District Litigation (MDL) | Historical EID And Chemours
Loss Contingencies [Line Items]
Amount awarded to other party						$ 335,000
PFOA Matters | PFOA Multi-District Litigation (MDL) | Chemours
Loss Contingencies [Line Items]
Amount awarded to other party			$ 29,000
NORTH CAROLINA | PFOA Matters
Loss Contingencies [Line Items]
Loss Contingency, New Claims Filed, Number | case				3
NORTH CAROLINA | PFOA Matters | Historical EID And Chemours
Loss Contingencies [Line Items]
Number of plaintiffs | plaintiff			200

COMMITMENTS AND CONTINGENT LI_5

COMMITMENTS AND CONTINGENT LIABILITIES - Environmental Matters (Details) $ in Millions	Mar. 31, 2021USD ($)case	Dec. 31, 2020USD ($)	Apr. 30, 2019case
Site Contingency [Line Items]
Accrual for environmental loss contingencies	$ 82	$ 80
Potential exposure in excess of accrual	$ 172
Historical EID And Chemours | Firefighter Foam Cases
Site Contingency [Line Items]
Number of lawsuits | case	1,020
Historical EID And Chemours | Water Contamination
Site Contingency [Line Items]
Number of lawsuits | case			10
Retained and Assumed at Divestiture
Site Contingency [Line Items]
Accrual for environmental loss contingencies	$ 37
Indemnification Agreement | DuPont
Site Contingency [Line Items]
Accrual for environmental loss contingencies	45
Indemnification Agreement | Dow | DuPont
Site Contingency [Line Items]
Accrual for environmental loss contingencies	8
Indemnification Agreement | Corteva | DuPont
Site Contingency [Line Items]
Accrual for environmental loss contingencies	$ 37

COMMITMENTS AND CONTINGENT LI_6

COMMITMENTS AND CONTINGENT LIABILITIES - Summary of Guarantees (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Guarantor Obligations [Line Items]
Maximum future payments	$ 180	$ 189
Customer and Supplier Guarantee Bank Borrowings
Guarantor Obligations [Line Items]
Maximum future payments	15
Equity Affiliates Guarantee Bank Borrowings
Guarantor Obligations [Line Items]
Maximum future payments	$ 165

OPERATING LEASES (Details)

OPERATING LEASES (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Leases [Abstract]
Operating lease cost	$ 29	$ 31
Operating lease payments	29	31
Operating lease assets and liabilities	$ 22	$ 53

OPERATING LEASES Schedule of _2

OPERATING LEASES Schedule of Leases (Details) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease right-of-use assets	[1]	$ 416	$ 423
Current operating lease liabilities	[2]	98	117
Noncurrent operating lease liabilities	[3]	320	308
Present value of lease liabilities		$ 418	$ 425
[1]	Included in "Deferred charges and other assets" in the interim Condensed Consolidated Balance Sheet.
[2]	Included in "Accrued and other current liabilities" in the interim Condensed Consolidated Balance Sheet.
[3]	Included in "Other noncurrent obligations" in the interim Condensed Consolidated Balance Sheet.

OPERATING LEASES Lease Term and

OPERATING LEASES Lease Term and Discount Rate (Details)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term (years)	7 years 7 months 17 days	6 years 9 months 10 days
Weighted average discount rate	2.06%	2.41%

OPERATING LEASES Maturities of

OPERATING LEASES Maturities of Lease Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Remainder of 2021	$ 83
2022	91
2023	70
2024	51
2025	30
2026 and thereafter	133
Total lease payments	458
Less: Interest	40
Present value of lease liabilities	$ 418	$ 425

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	22 Months Ended
	Mar. 31, 2021	Mar. 31, 2021	Feb. 01, 2021	Jun. 01, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock repurchase amount	$ 1,500	$ 1,500		$ 2,000
Stock repurchased and retired (in shares)	6.8	23.7
Payments for repurchase of common stock	$ 500	$ 1,500
Discontinued Operations | Nutrition & Biosciences Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shares exchanged in exchange offer			141.7
Shares accepted and retired in exchange offer			197.4

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	$ 27,705	$ 40,117	$ 39,070	$ 41,556
Total other comprehensive loss	(214)	(402)
Ending balance	27,705	40,117
Cumulative Translation Adj
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	177	(1,466)	470	(1,070)
Other comprehensive (loss) income before reclassifications	(477)	(396)
Amounts reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive loss	(293)	(396)
Ending balance	177	(1,466)
Cumulative Translation Adj | N&B Segment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	184
Pension and OPEB
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(340)	(343)	(425)	(345)
Other comprehensive (loss) income before reclassifications	8	(2)
Amounts reclassified from accumulated other comprehensive loss	4	4
Total other comprehensive loss	85	2
Ending balance	(340)	(343)
Pension and OPEB | N&B Segment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	73
Derivative Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	0	(1)	(1)	(1)
Other comprehensive (loss) income before reclassifications	0	0
Amounts reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive loss	1	0
Ending balance	0	(1)
Derivative Instruments | N&B Segment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	1
Total
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning balance	(163)	(1,810)	$ 44	$ (1,416)
Other comprehensive (loss) income before reclassifications	(469)	(398)
Amounts reclassified from accumulated other comprehensive loss	4	4
Total other comprehensive loss	(207)	(394)
Ending balance	(163)	$ (1,810)
Total | N&B Segment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Amounts reclassified from accumulated other comprehensive loss	$ 258

STOCKHOLDERS' EQUITY - Summar_2

STOCKHOLDERS' EQUITY - Summary of Reclassifications Out of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Pension and other post-employment benefit plans
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax		$ (4)	$ (4)
Pension and other post-employment benefit plans | Total Company
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before tax	[1]	106	3
Tax (benefit) expense	[1]	(29)	1
After tax		77	4
Cumulative Translation Adj
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax		0	0
Cumulative Translation Adj | Total Company
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax	[1]	(184)	0
Derivative Instruments
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax		0	0
Derivative Instruments | Total Company
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax	[1]	(1)	0
Total
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax		(4)	(4)
Total | Total Company
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
After tax		$ (262)	$ (4)
[1]	The activity for the three months ended March 31, 2021 is classified within "Income (loss) from discontinued operations, net of tax" and "Sundry income (expense) - net" as part of the N&B Transaction and continuing operations, respectively. The activity for the three months ended March 31, 2020 is classified within the "Sundry income (expense) - net" and "Provision for income taxes on continuing operations" lines.

NONCONTROLLING INTERESTS (Detai

NONCONTROLLING INTERESTS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period	$ 566	$ 569
Net income attributable to noncontrolling interests	4	6
Distributions to noncontrolling interests	(19)	(6)
Cumulative translation adjustments	(7)	(8)
Split-off of N&B	(27)	0
Other	0	5
Balance at end of period	$ 517	$ 566

PENSION PLANS AND OTHER POST-_3

PENSION PLANS AND OTHER POST-EMPLOYMENT BENEFITS (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Feb. 01, 2021
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost - total		$ (12)	$ (11)
Additional contributions		75
Discontinued Operations | Nutrition & Biosciences
Defined Benefit Plan Disclosure [Line Items]
Status of plan				$ (232)
Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost	[1]	15	18
Interest cost	[2]	11	14
Expected return on plan assets	[3]	(28)	(28)
Amortization of prior service credit	[4]	(1)	(1)
Amortization of net loss	[5]	3	4
Curtailment/settlement	[6]	2	0
Net periodic benefit cost - total		2	7
Discontinued Operations | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic benefit cost - total		1	4
Continuing Operations | Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Service cost		13	14
Interest cost		11	13
Expected return on plan assets		(27)	(26)
Amortization of prior service credit		(1)	(1)
Amortization of net loss		3	3
Curtailment/settlement		2
Net periodic benefit cost - total		$ 1	$ 3
[1]	The service cost from continuing operations was $13 million and $14 million for the three months ended March 31, 2021 and 2020, respectively.
[2]	The interest cost from continuing operations was $11 million and $13 million for the three months ended March 31, 2021 and 2020, respectively.
[3]	The expected return on plan assets from continuing operations was $27 million and $26 million for the three months ended March 31, 2021 and 2020, respectively.
[4]	The amortization of prior service credit from continuing operations a gain of $1 million for both the three months ended March 31, 2021 and 2020.
[5]	The amortization of unrecognized net loss from continuing operations was $3 million for both the three months ended March 31, 2021 and 2020.
[6]	The curtailment and settlement costs from continuing operations was $2 million for the three months ended March 31, 2021. There were no curtailment or settlement costs from continuing operations for the three months ended March 31, 2020.

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Compensation expense	$ 17	$ 38
Income tax benefits	$ 3	$ 8
Stock options granted (in shares)	0.6
Weighted-average stock option price (in usd per share)	$ 16.92
Weighted-average stock options exercise price (in usd per share)	$ 72.98
DuPont 2020 Equity and Incentive Plan [Domain]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Capital shares reserved for future issuance	18
DuPont Omnibus Incentive Plan [Domain]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Capital shares reserved for future issuance	2
Restricted Stock Units (RSUs)
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares granted (in shares)	0.6
Weighted-average share price (in usd per share)	$ 72.88
Performance Shares
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Shares granted (in shares)	0.4
Weighted-average share price (in usd per share)	$ 78.23

FINANCIAL INSTRUMENTS (Summary

FINANCIAL INSTRUMENTS (Summary of Fair Value of Financial Instruments) (Details) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Long-term debt including debt due within one year, Cost		$ (12,622)	$ (15,612)
Long term debt including debt due within one year, Gain		0	0
Long term debt including debt due within one year, Loss		(2,002)	(2,725)
Long term debt including debt due within one year, Fair Value		(14,624)	(18,337)
Derivative assets (liabilities), Gain		13	4
Derivative assets (liabilities), Loss		(10)	(13)
Derivative assets (liabilities), Fair Value		3	(9)
Marketable securities		2,001	0
Total cash equivalents, restricted cash equivalents and marketable securities		5,261	7,328
Cash equivalents, restricted cash equivalents and marketable securities, Gain		0	0
Cash equivalents, restricted cash equivalents and marketable securities, Loss		0	0
Cash equivalents, restricted cash equivalents and marketable securities, Fair Value		5,261	7,328
Cash and Cash Equivalents | Cash Equivalents
Debt Securities, Available-for-sale [Line Items]
Cash equivalents, Cost		3,246	1,105
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0	0
Cash and Cash Equivalents, Fair Value Disclosure		3,246	1,105
Cash and Cash Equivalents | Restricted cash equivalents
Debt Securities, Available-for-sale [Line Items]
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax	[1]	0	0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax	[1]	0	0
Restricted cash equivalents, Cost	[1]	14	6,223
Debt Securities | Marketable securities
Debt Securities, Available-for-sale [Line Items]
Marketable securities, Fair Value		2,001	0
Marketable securities, Loss		0	0
Marketable securities		2,001	0
Marketable securities, Gain		0	0
Foreign Exchange Contract
Debt Securities, Available-for-sale [Line Items]
Derivative assets (liabilities), Gain	[2]	13	4
Derivative assets (liabilities), Loss	[2]	(10)	(13)
Derivative assets (liabilities), Fair Value	[2]	$ 3	$ (9)
[1]	Classified as "Other current assets" in the interim Condensed Consolidated Balance Sheets.
[2]	Presented net of cash collateral where master netting arrangements allow.

FINANCIAL INSTRUMENTS Notional

FINANCIAL INSTRUMENTS Notional Amounts (Details) - USD ($) $ in Millions		Mar. 31, 2021	Dec. 31, 2020
Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivative [Line Items]
Derivative, notional amount	[1]	$ 84	$ (304)
[1]	Presented net of contracts bought and sold.

FINANCIAL INSTRUMENTS (Derivati

FINANCIAL INSTRUMENTS (Derivatives) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Other Nonoperating Income (Expense) | Not Designated as Hedging Instrument | Foreign Exchange Contract
Derivatives, Fair Value [Line Items]
Foreign currency derivatives gain (loss) not designated as hedge	$ 20	$ 4

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Millions		Mar. 31, 2021		Dec. 31, 2020
Liabilities at fair value:
Long term debt including debt due within one year, Fair Value		$ 14,624		$ 18,337
Offsetting counterparty and cash collateral netting amount for assets		7		9
Offsetting counterparty and cash collateral netting amount for liabilities		7		9
Recurring | Level 2
Assets at fair value:
Cash equivalents and restricted cash equivalents	[1]	3,260		7,328
Marketable securities	[2]	2,001
Total assets at fair value		5,281		7,341
Liabilities at fair value:
Long term debt including debt due within one year, Fair Value	[3]	14,624		18,337
Total liabilities at fair value		14,641		18,359
Recurring | Level 2 | Foreign currency
Assets at fair value:
Foreign currency contracts	[5]	20	[4]	13	[6]
Liabilities at fair value:
Foreign currency contracts	[5]	$ 17	[4]	$ 22	[6]
[1]	Treasury bills, time deposits, and money market funds included in "Cash and cash equivalents" and money market funds included in "Other current assets" in the interim Condensed Consolidated Balance Sheets and held at amortized cost, which approximates fair value.
[2]	Primarily time deposits with maturities of greater than three months at time of acquisition.
[3]	Fair value is based on quoted market prices for the same or similar issues, or on current rates offered to the company for debt of the same remaining maturities and terms.
[4]	Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $7 million for both assets and liabilities as of March 31, 2021.
[5]	See Note 20 for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.
[6]	Asset and liability derivatives subject to an enforceable master netting arrangement with the same counterparty are presented on a net basis in the Consolidated Balance Sheets. The offsetting counterparty and cash collateral netting amounts were $9 million for both assets and liabilities as of December 31, 2020.

SEGMENTS AND GEOGRAPHIC REGIO_3

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Operating Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 3,976	$ 3,670
Operating EBITDA	1,047	907
Equity in earnings of nonconsolidated affiliates	26	39
Electronics & Industrial
Segment Reporting Information [Line Items]
Net sales	1,300	1,115
Operating EBITDA	436	327
Equity in earnings of nonconsolidated affiliates	9	9
Water & Protection
Segment Reporting Information [Line Items]
Net sales	1,328	1,276
Operating EBITDA	355	357
Equity in earnings of nonconsolidated affiliates	12	7
Mobility & Materials
Segment Reporting Information [Line Items]
Net sales	1,215	1,091
Operating EBITDA	278	215
Equity in earnings of nonconsolidated affiliates	3	1
Corporate
Segment Reporting Information [Line Items]
Net sales	133	188
Operating EBITDA	(22)	8
Equity in earnings of nonconsolidated affiliates	$ 2	$ 22

SEGMENTS AND GEOGRAPHIC REGIO_4

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Reconciliation of Operating EBITDA (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting [Abstract]
Income (loss) from continuing operations, net of tax	$ 541	$ (550)
Provision for income taxes on continuing operations	32	94
Income (Loss) from continuing operations before income taxes	573	(456)
Depreciation and amortization	328	345
Interest income	2	2
Interest expense	146	171
Non-operating pension/OPEB benefit	(12)	(11)
Foreign exchange losses, net	(9)	(3)
Significant items	5	857
Operating EBITDA	$ 1,047	$ 907

SEGMENTS AND GEOGRAPHIC REGIO_5

SEGMENTS AND GEOGRAPHIC REGIONS - Summary of Certain Items by Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Integration and separation costs	$ (6)	$ (123)
Restructuring and asset related charges - net	(2)	(128)
Goodwill impairment charge	0	(533)
Asset impairment charges		(270)
Gain on divestiture	3	197
Significant items	(5)	(857)
Electronics & Industrial
Segment Reporting Information [Line Items]
Integration and separation costs	0	0
Restructuring and asset related charges - net	0	(4)
Goodwill impairment charge		0
Asset impairment charges		0
Gain on divestiture	2	197
Significant items	2	193
Water & Protection
Segment Reporting Information [Line Items]
Integration and separation costs	0	0
Restructuring and asset related charges - net	0	(25)
Goodwill impairment charge		0
Asset impairment charges		0
Gain on divestiture	0	0
Significant items	0	(25)
Mobility & Materials
Segment Reporting Information [Line Items]
Integration and separation costs	0	0
Restructuring and asset related charges - net	0	(25)
Goodwill impairment charge		0
Asset impairment charges		0
Gain on divestiture	0	0
Significant items	0	(25)
Corporate
Segment Reporting Information [Line Items]
Integration and separation costs	(6)	(123)
Restructuring and asset related charges - net	(2)	(74)
Goodwill impairment charge		(533)
Asset impairment charges		(270)
Gain on divestiture	1	0
Significant items	$ (7)	$ (1,000)